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ATP releaseThe ﬁeld of hemichannels is closely related to the purinergic signaling and both areas have been growing in
parallel. Hemichannels open in response to a wide range of stressful conditions, such as ischemia, pressure or
swelling. Hemichannels represent an important mechanism for the cellular release of adenosine 5′-triphos-
phate (ATP), which is an agonist of the P2Y and P2X family of purinergic receptors. Therefore, hemichannels
are key molecules in the regulation of purinergic receptor activation, during physiological and pathophysio-
logical conditions. Furthermore, purinergic receptor activation can also lead to the opening of hemichannels
and the subsequent ampliﬁcation of purinergic signaling via a positive signaling feedback loop, giving rise to
the concept of ATP-induced ATP release. Purinergic receptor signaling is involved in regulating many physi-
ological and pathophysiological processes. P2Y receptors activate inositol trisphosphate and transiently in-
crease intracellular calcium. This signaling opens both connexin and pannexin channels, therefore
contributing to the expansion of calcium waves across astrocytes and epithelial cells. In addition, several of
the P2X receptor subtypes, including the P2X2, P2X4 and P2X7 receptors, activate select cellular permeation
pathways to large molecules, including the pannexin-1 channels, which are involved in the initiation of in-
ﬂammatory responses and cell death. Consequently, the interplay between purinergic receptors and hemi-
channels could represent a novel target with substantial therapeutic implications in areas such as chronic
pain, inﬂammation or atherosclerosis. This article is part of a Special Issue entitled: The communicating junc-
tions, roles and dysfunctions.
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1.1. Historic perspective of purinergic signaling pathways
In 1929, Drury and Szent-Gyorgyi described the potent actions of
the extracellular application of adenine compounds on the heart [1].
Four decades later, ATP was proposed as the transmitter responsible
for non-adrenergic, non-cholinergic transmission in the gut and blad-
der. In 1972 Burnstock introduced the concept of purinergic signaling
[2], in which extracellular purines (most notably ATP, adenosine, and
pyrimidine) act as extracellular signaling molecules. Both, pyrimidine
and purine nucleotides, are released from cells through several phys-
iologically relevant mechanisms, including diffusion through mem-
brane hemichannels, activation of membrane transporters and
vesicular exocytosis [3–6]. In addition, purines and pyrimidines are
released from dying cells: this being an early indicator for cell damage
[5,7]. Upon release, ATP (and other nucleotides) are enzymatically de-
graded within seconds by an extended family of ectonucleotidases
[8]. This process is physiologically relevant as ATP metabolites are
also agonists of purinergic receptors (Fig. 1). These purinergic signal-
ing molecules activate three receptor classes: metabotropic P1 recep-
tors, which are activated by adenosine, while the nucleotide receptors
comprise the P2 family and are subdivided into P2Ymetabotropic and
P2X ionotropic sub-classes (Fig. 1) [6,9–13].
The purinergic signaling is a primitive system, ATP is an ancient
and fundamentally important biological molecule. There are puriner-
gic receptors in ancestral green algae and early in the fungi lineage
[14,15]. Purinergic signaling is implicated in many neuronal and
non-neuronal mechanisms, including exocrine and endocrine secre-
tion, immune responses, inﬂammation, pain, platelet aggregation
and endothelial-mediated vasodilatation [16,17]. In addition, puriner-
gic signaling processes are implicated in mediating cell proliferation,
differentiation and death [18,19]. ATP-mediated signaling has been
identiﬁed in virtually all tissues and cell types and appears to be the
most widespread and omnipresent of all known extracellular signal-
ing molecules.
1.2. P1 or adenosine receptors
The P1 class of purinergic receptor was ﬁrst described in 1989 and
comprises four subtypes: A1, A2A, A2B and A3 (Fig. 1) [20–25]. The no-
menclature used follows the Alexander et al. guide [26]. In commonwith other G protein-coupled receptors, they contain seven trans-
membrane (TM) domains of approximately 21 to 28 hydrophobic
amino acids composing a α-helix structure. The amino-terminus of
the protein is present on the extracellular side of the plasma mem-
brane, while the protein's carboxy-terminus lies on the cytoplasmic
side of the membrane. A pocket for the ligand-binding site is formed
by the three-dimensional arrangement of the α-helical TM domains,
and the agonist is believed to bind within the upper half of this
pore [11]. Binding of the agonist to the receptor gives rise to a stable
conﬁguration as has been shown by x-ray crystallography with the
A2A receptor [27]. The TM domains are connected by three extracellu-
lar and three cytoplasmic hydrophilic loops [11]. P1 receptors are
coupled to adenylate cyclase signaling pathways in which A1 and A3
receptor activations have inhibitory effects on adenylate cyclase
through the Gi/o protein α-subunits. Activation of the A2A and A2B re-
ceptors stimulates the production of cyclic AMP (cAMP) via adenylate
cyclase through the Gs protein [6,22,28].
A number of selective agonists and antagonists have been identi-
ﬁed for several of the P1 adenosine receptor subtypes including ago-
nists for the A1, A2A and A2B receptors, and antagonists for the A1, A2B
and A3 receptors [11].1.3. Purinergic P2Y receptors
The ﬁrst P2Y receptor (P2Y1) was cloned in 1993 [29,30], and
since then several other subtypes have been isolated. Eight human
P2Y receptor subtypes have so far been identiﬁed, the P2Y1, P2Y2,
P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors [12,31] (Fig. 1).
A number of putative P2Y receptor subtypes have also been identiﬁed
but these correspond to non-mammalian orthologs, or receptors with
sequence homology to P2Y receptors, but for which there is no func-
tional evidence of activation by nucleotides. Recently, the orphan re-
ceptor GPR80/GPR99 was named P2Y15 receptor on the basis that it
would be activated by AMP [32].
Molecular studies have shed light upon the mechanisms of recep-
tor activation. Site-directed mutagenesis of the P2Y1 and P2Y2 recep-
tors has shown that some positively charged residues in TM3, TM6
and TM7 are crucial for receptor activation by nucleotides [33,34].
Furthermore four cysteine residues in the extracellular loops, which
are conserved in P2Y receptors, are known to be essential for proper
trafﬁcking of the receptor to the cell surface [35].
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Fig. 1. The purinergic receptor family. Extracellular ATP is the agonist of both P2X and P2Y receptors and is also the substrate of ectonucleotidases, which degrade ATP to adenosine
and transiently generate ADP, providing the agonist for P2Y receptors. Adenosine, the ﬁnal product of adenine nucleotide hydrolysis, activates P1 or adenosine receptors. P2X re-
ceptors are ionotropic and their activation opens a cationic conduit, resulting in cellular hyperpolarization via K+ efﬂux and extracellular Na+ and Ca2+ inﬂux. P2Y receptors are
metabotropic G-protein coupled receptors and their activation leads to phospholipase C activation, generation of inositol trisphosphate and rise of cytosolic Ca2+ from intracellular
stores, alternatively P2Y receptors could also couple to adenylate cyclase activation. Adenosine receptors are also G-protein coupled receptors that differentially regulate the pro-
duction of cAMP; whereas A2A and A2B activate adenylate cyclase and increase the levels of cAMP, A1 and A3 receptors inhibit adenylate cyclase.
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sitol trisphosphate (IP3) second messenger systems [12]. The lack of
potent and selective agonists and antagonists for many of the P2Y re-
ceptor subtypes has limited research in this ﬁeld to focus upon study-
ing the P2Y1, P2Y4, P2Y13 and P2Y14 receptors. The most striking
difference between the P2Y receptor subtypes is their ability to use
different natural nucleotides as agonists. The P2Y1, P2Y12, and P2Y13
receptors preferentially utilize ADP, while P2Y11 has a high afﬁnity
for ATP. The P2Y2 and P2Y4 receptors utilize UTP while UDP is the ag-
onist for the P2Y6 receptor. Finally UDP-sugars activate the P2Y14 re-
ceptor [12]. The various P2Y receptors are functionally coupled to
distinct G proteins and therefore their downstream signaling varies
among subtypes, activating phospholipase C (PLC), IP3, intracellular
calcium increase or cAMP production [12]. Suramin and pyridoxal-
phosphate-6-azophenyl-2′,4′-disulphonic acid (PPADS) are non-
selective antagonists of the P2Y receptors, but also antagonize the
P2X receptors (see later Section 1.4). The PLC inhibitor U73122 is
commonly used to block the intracellular calcium rise associated
with P2Y receptor mediated downstream signaling [36]. Recently, se-
lective antagonists for P2Y1, P2Y12 and P2Y13 receptors have been de-
veloped by the pharmaceutical industry [12].
1.4. Purinergic P2X receptors
The ionotropic P2X receptors are ATP-gated cation channels, se-
lective for Na+, K+ and Ca2+ ions [37]. The ﬁrst cDNA encoding a
P2X receptor (P2X1) was isolated in 1994 [38,39] and since then,
seven different P2X receptor subunits have been identiﬁed (P2X1 to
P2X7) [6,37,40].
The members of this receptor family show conserved subunit to-
pology. They comprise two TM spanning regions and possessintracellular amino- and carboxy-terminus which contain consensus
binding motifs for protein kinases. A large extracellular loop exits
which contains 10 conserved cysteine residues and is capable of
forming a series of disulﬁde bridges. The ﬁrst TM is involved in chan-
nel gating while the second lines the ion pore in the membrane
[37,41–44]. P2X receptor subunits are capable of forming functional
homomeric and heteromeric trimers.
1.4.1. Homomeric P2X receptors
P2X receptor homomeric subtypes are non-speciﬁc cation chan-
nels and after activation there is an inﬂux of calcium and sodium.
The P2X1, P2X2, P2X3, P2X4 and P2X7 are the most studied P2X re-
ceptor subunits. P2X1 and P2X3 show a fast desensitization in con-
trast to the P2X2, P2X4 and P2X7 receptors. While α,β-methylene
ATP (αβ-meATP) is a potent agonist for P2X1 and P2X3 receptors,
there are no speciﬁc ligands for the P2X2 receptor [39,45,46]. Sura-
min, PPADS and 2′,3′-O-(2,4,6-Trinitrophenyl) (TNP)-ATP can be
used as non-selective P2X antagonists [47], but speciﬁc antagonists
for P2X1 and P2X3 receptors now exist [45,46]. Homomeric P2X4 re-
ceptors are activated by ATP but not by αβme-ATP. ATP-evoked cur-
rents at P2X4 receptors are potentiated by ivermectin, cibacron blue
and zinc [46,48]. Prolonged ATP application of several seconds, to
P2X2 and P2X4 receptor channels results in an increasing permeabil-
ity to large organic cations such as N-methyl-D-glucamine (NMDG)
[49]. This increase in permeability is also the main feature of the
homomeric P2X7 receptor, inducing the opening of a large pore that
allows large dye molecules, such as ethidium bromide or YO-PRO-1,
to enter the cell (see Section 3.1). Among all the P2X receptors,
P2X7 receptor stimulation induces structural changes in the cell
such as microvesicle shedding, membrane blebbing, activation of
MAPK and ultimately cell death [50–52]. A potent agonist for the
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BzATP is an effective agonist at similar or lower concentrations at
other P2X receptors [37,46]. Selective antagonists for P2X7 receptor
have been developed by pharmaceutical companies as potential
anti-inﬂammatory drugs [53].
1.4.2. Heteromeric P2X receptors
Heteromeric receptor subunits were ﬁrst described after their co-
expression in Xenopus oocytes and subsequent functional analysis
using voltage patch clamp. The most physiologically relevant of
these heteromeric receptors are the P2X1/2, P2X2/3, P2X1/4 and
P2X1/5 receptors. P2X1 and P2X2 receptors co-expression yielded a
mixed population of homomeric and heteromeric receptors. The het-
eromeric P2X1/2 ion channels showed a novel sensitivity to extracel-
lular pH [54]. It has been claimed that trimeric P2X1/2 receptors
incorporate one P2X1 and two P2X2 subunits [54–56]. P2X2/3 het-
eromeric channels are characterized by a sustained current elicited
by αβ-meATP [46,56,57]. They also share some properties with
homomeric P2X2 receptors in that they are potentiated by low pH,
and they desensitize slowly [57,58]. Voltage clamp experiments
revealed functional P2X receptors with kinetic properties resembling
that of homomeric P2X4 receptors, and a pharmacological proﬁle
similar to homomeric P2X1 receptors [49]. The deﬁning phenotype
of the P2X1/5 heteromer is a sustained current evoked by αβ-
meATP and a higher sensitivity to ATP. This is not seen in the P2X1
and P2X5 homomeric channels [5,46,59].
1.5. Purinergic receptors and hemichannels
Gap junctions are intercellular channels that allow the passage of
ions and other small molecules between neighboring cells. They are
formed from two multimeric subunits called hemichannels or con-
nexons that reside in the plasma membranes of two closely opposed
cells. Connexons are composed of six transmembrane protein sub-
units called connexins, with intracellular amino- and carboxy-
termini. Several connexins have been reported to form functional
hemichannels when expressed in Xenopus oocytes [60], raising the in-
triguing possibility that connexons may function as transmembrane
ion channels in addition to serving as precursors in the formation of
gap junction channels [61]. The opening of hemichannels occurs in
response to many physiological and pathological situations, including
volume regulation, proliferation, calcium wave propagation by extra-
cellular messengers, and cell death during metabolic inhibition [62]. It
is well known that hemichannels allow permeability to diverse intra-
cellular molecules, such as IP3, ATP, glucose, glutamate or prostaglan-
dins [63]. Numerous connexins have been proposed to release ATP
under different stimuli, including connexins 26, 32, 37 and 43
[64–67]. However, connexons are not the only hemichannels releas-
ing ATP, and recently pannexins, mainly pannexin-1, have been im-
plicated in this phenomenon [68]. Pannexin-1 is a member of the
mammalian pannexin family of proteins, a family with homology to
the invertebrate gap junction proteins, the innexins. Pannexin-1
form channels, or pannexons, that open in non-junctional surface
membrane in several vertebrate cell types. Although transfected
pannexin-1 can induce electrical coupling of Xenopus oocytes [69],
presumably via gap junctions, unlike connexins, pannexin-1 may
not form gap junctions in mammalian tissues and cells [70].
In 1986 Gordon hypothesized that the release process for ATP
could involve changes in the topography of plasma membrane con-
stituents, resulting in the opening of pores that allows the selective
release of some low molecular weight cytoplasmic constituents [71].
Since then, there has been a signiﬁcant increase in studies investigat-
ing this process and it is now known that hemichannels form pores in
the plasma membrane of the cells that account for the physiological
release of ATP to the extracellular milieu and are thus considered as
initiators or enhancers of the purinergic signaling [72] (Fig. 2). Onthe other hand, several purinergic receptors have been linked to the
opening of hemichannels, generating a positive feedback loop to am-
plify the purinergic signaling [73,74] (Fig. 2). However, it should be
stressed that many aspects of the interactions between pannexin
channels or connexin hemichannels and purinergic receptors have
not been clariﬁed.
1.6. Limitations of hemichannel research tools
There are several approaches to investigate the function of hemi-
channels, including the use of blockers, genetic knock down/out sys-
tems, and conductance or permeation measurements to different
endogenous molecules such as ATP or charged ﬂuorescent tracer mol-
ecules. They all have their disadvantages and as such, there is no con-
clusive technique to identify the nature of hemichannels. Therefore a
combination of techniques is commonly used to characterize hemi-
channel opening kinetics. Hemichannel pharmacology is not speciﬁc,
and different blockers inhibit different connexin and/or pannexin
channels [63]. In addition, these inhibitors could have non-
hemichannel targets and often blocks other channels [75,76].
Therefore extreme care must be taken to ensure that they do not
affect purinergic receptor activation in a particular experimental
condition. Genetic knock down/out systems could present strong
compensatory effects, since more than one hemichannel subtype are
expressed, and knock down of a speciﬁc subtype could lead to a
compensatory response via the function of other hemichannel [77].
Unitary conductance varies among the different hemichannels and
does not correlate with the size of the permeant pore [78,79]. The
use of ﬂuorescent charged trace molecules has been successfully
and extensively used to report the existence of hemichannels, but
they are usually accumulative dyes and data interpretation
regarding to hemichannels closing is difﬁcult to obtain.
2. How hemichannels modulate purinergic receptors
ATP release to the extracellular environment can serve as a phys-
iological signal for intercellular communication as well as a noxious
signal that promotes cell death. ATP acts mainly as an autocrine/
paracrine signal,modulating a variety of cellular functions by activating
ionotropic P2X or metabotropic P2Y receptors (see Section 1) [13].
Several studies propose a tight relationship between ATP release
through hemichannels and activation of the purinergic signaling in
the surrounding cells, with different physiological or pathophysiologi-
cal roles (summarized in Fig. 3).
2.1. Connexin channels activating P2 receptors
2.1.1. Corneal endothelial cell communication
Intercellular Ca2+ wave propagation is a form of cell–cell commu-
nication. In corneal endothelial cells, intercellular Ca2+ wave propa-
gation evoked by mechanical stimulation is partially mediated by
ATP release and the subsequent activation of P2Y receptors in neigh-
boring cells. For example, in bovine corneal endothelial cells (BCECs),
ATP is released through connexin hemichannels. Experiments using
hemichannel blockers such as ﬂufenamic acid or the connexinmimet-
ic peptide Gap26, signiﬁcantly reduced ATP-mediated Ca2+ propaga-
tion in conﬂuent monolayers of BCECs as well as in contact-free cells
[80]. The presence of connexin (Cx) 43 has been demonstrated in
BCECs [81], and in human corneal endothelial cells [82]. Suramin
(a non-selective P2 receptor antagonist) and apyrase application
suppressed intercellular Ca2+ wave propagation in BCECs after
mechanical stimulation. Furthermore Ca2+ wave propagation was
augmented after exposure to an ectonucleotidase inhibitor [83], sug-
gesting a secondary paracrine action of extracellular ATP through
purinergic receptors.
Fig. 2. ATP-induced ATP release. Hemichannel activation represents a well-established pathway for the release of ATP, which serve as an agonist for purinergic receptors. Activation
of different purinergic receptors (like P2X7 or P2Y receptors) leads to the opening of hemichannels, generating a positive feedback-signaling loop. P2X7R receptors probably open
hemichannels via its intracellular Ct region, whereas P2Y receptors use IP3 to open hemichannels.
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Themammalian cochlea is a snail-shaped inner ear structure divid-
ed in three chambers, namely the scala vestibuli, the scala tympani, and
the scala media. The epithelium comprises the organ of Corti (OoC), a
sensory organwhich rests on the basilar membrane and is responsible
for sound transduction. The OoC has the form of an epithelial ridge
encompassing highly specialized sensory inner hair cells (IHCs) and
outer hair cells (OHCs) [84]. Connexin hemichannels in the cochlea
can release ATP at concentrations that account for the submicromolar
concentrations measured in the cochlear ﬂuids in vivo. Connexin
hemichannels can open to release ATP by a reduction in the extracel-
lular Ca2+ concentration or by mechanical stimulation. Nanomolar
concentrations of extracellular ATP elicit inward currents in OHCs
and also alter OHC electromotility. P2 receptor expression has been
identiﬁed in cochlear cells, including OHCs [85] and P2X receptor an-
tagonists inhibit styryl dye entry into hair cells [86]. The subcellular lo-
cation of P2X receptors in hair cells and the endogenous presence of
extracellular ATP in cochlear tissue, P2X receptors could partiallyATP
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tracellular calcium decrease), inducing the release of ATP which in turns activate purinergimediate rapid styryl dye entry into hair cells, producing a spatial pat-
tern similar to a transduction-mediated mechanism [86]. P2 receptors
blockade abrogates the effect of ATP on OHC electromotility. ATP re-
leased from cochlear-supporting cells via connexin hemichannels en-
ters into the endolymph and perilymph. This ATP consequently acts on
the P2 receptors on the OHC cells to mediate electromotility [67].
In addition, it has been found that part of the ERK1/2 signal in the co-
chlea depends on Ca2+ inﬂux, indicating a role for the damage-
induced Ca2+ wave in this signaling and implicating ionotropic P2X
receptors as potential mediators [87]. Majumder et al. [88] showed
that Cx26 and Cx30 form hemichannels that allow the release of ATP
from the endolymphatic surface of cochlear supporting and epithelial
cells and also form gap junction channels that allow the concomitant
intercellular diffusion of Ca2+-mobilizing second messengers. Re-
leased ATP in turn activates G-protein coupled P2Y2 and P2Y4 recep-
tors, PLC-dependent generation of IP3 and increased cytosolic Ca2+
release from intracellular stores, thereby instigating the regenerative
propagation of intercellular Ca2+ signals [88].2 Receptors
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Mechanical loading of articular chondrocytes triggers release of
ATP into the pericellular microenvironment [89]. This ATP and its de-
rivatives activate purine receptors on the cell membrane to trigger
autocrine and paracrine mechanotransduction signaling cascades, in-
volving intracellular Ca2+. In various cell types, primary cilia function
as mechanoreceptors and deﬂection of the cilium initiates intracellu-
lar Ca2+ signaling as part of a mechanotransduction signaling cascade
[90]. The primary cilia are involved in purinergic Ca2+-signaling me-
diated chondrocyte mechanosensitivity. The cilium acts as a mechan-
osensor triggering the release of ATP, probably through Cx43
hemichannels, and subsequent signaling through P2 receptors. Cx43
is expressed in bovine chondrocyte primary cilia and human chon-
drocytes, but its expression was conﬁned to the upper 200 μm of
the tissue closest to the articular surface [91]. The fact that these po-
tential mechanosensitive cells are primarily in the superﬁcial/middle
zone of articular cartilage may indicate that the mechanotransduction
pathways in these cells are different to those which may operate in
deeper tissue zones [92]. The loss of Cx43 expression in deep tissue
zones and their enhanced expression in agarose culture may be relat-
ed to the oxygen levels in the cell environment, as hypoxia is known
to regulate Cx43 dephosphorylation, translocation and proteosomal
degradation in some cell types [93]. Recently, the expression of
pannexin-3 has been found in chondrocytes [94,95] and it has been
proposed as ATP release conduit, which regulates intracellular ATP
and cAMP levels, promoting chondrocyte differentiation [95]. Similar-
ly, human articular chondrocytes showed positive immunoﬂuores-
cence labeling for purine receptors: P2Y1, P2Y2, P2X2, P2X4 and
P2X7 [91], and these have been shown to be functional by the activa-
tion of intracellular Ca2+ rise following the addition of exogenous
ATP [96] and by inhibition using non-selective purinergic antagonists
such as suramin [97].
2.1.4. Astrocytes: traumatic brain injury
Traumatic brain injury leads to the development of gliosis, which
is characterized by hypertrophic and hyperplastic changes of astro-
cytes in response to brain injury. ATP is released from astrocytes
after stretch-induced injury. Cx43 is a perfect candidate to aid release
of ATP from astrocytes, since Cx43 is the main gap junction protein
expressed in this cell type [98] and mechanical stretch is a well-
related signal to activate Cx43 hemichannel opening [74]. Although
pannexin-1 has recently also been characterized as an ATP release
conduit in astrocytes [99], it is unclear if pannexin-1 opens in re-
sponse to mechanical stimulation [74,100]. Extracellular ATP stimu-
lates ERK kinase in astrocytes by a signaling process mediated by P2
purinergic receptors. ERK is rapidly phosphorylated after stretch-
induced injury of cultured astrocytes by a calcium-dependent path-
way in which ATP release contributes to its activation by stimulating
P2X2 and P2Y1 purinergic receptors [101]. Furthermore, P2X7 recep-
tor activation has also been associated with brain injury or trauma in-
ducing neuronal death. In these situations, it has been demonstrated
that ATP is released by activated microglia and astrocytes [102].
2.1.5. Pathogenesis of atherosclerosis
Atherosclerosis is a progressive disease characterized by accumu-
lation of macrophages, T lymphocytes, smooth muscle cells (SMCs)
and lipids in the vascularwall in large- andmedium-sized arteries. En-
dothelial dysfunction leads to the increase in cell adhesion molecules
and secretion of chemo-attractants. The development of the athero-
sclerotic plaque is correlated with changes in the pattern of vascular
connexin expression [103], and depending on Cx40/Cx43 ratio, the
signaling pathwaywill be anti- or pro-inﬂammatory [104]. Circulating
leukocytes release ATP, mainly via Cx37 hemichannels in monocytes
[105]. ATP is subsequently converted ﬁrst to AMP by CD39 or ecto-
nucleoside triphosphate diphosphohydrolase 1 (ENTPD1), which is
located on the surface of leukocytes and endothelial cells (ECs). AMPis then converted to adenosine by CD73 or ecto-5′-nucleotidase
(NT5E) (located on the surface of ECs). In physiological environments,
Cx40 is expressed in ECs, and the conversion rate favors the
production of adenosine, which activates adenosine A2B receptors on
the endothelium. A2B activation triggers cAMP-dependent signaling,
which further activates CD73, andmaintains the expression of endothe-
lial adhesion molecules for leukocytes (such as VCAM-1) to very low
levels [106]. This prevents leukocyte adhesion along the endothelium,
thus providing an anti-inﬂammatory mechanism. In the presence of a
pro-inﬂammatory stimulus, the expression of Cx40 decreases while
that of Cx43 increases [107]. In the absence of Cx40, CD73 activity is de-
creased [108], which results in an attenuation of adenosine production
and a subsequent increase in leucocyte adhesion. The decrease of CD73
activity also induces an increase in extracellular ATP, which in turn ac-
tivates purinergic receptors (P2Y) on ECs, triggering Ca2+-dependent
signaling. Ca2+ waves propagates through Cx43-made gap junction
channels and increase the expression of endothelial adhesionmolecules
for leukocytes (i.e. P-selectin), therefore promoting leukocyte adhesion
and providing a pro-inﬂammatory mechanism [104].
2.1.6. Nanoparticles and DNA damage
Nanoparticles have a speciﬁc capacity for drug loading, high
superparamagnetism, efﬁcient photoluminescence and distinctive
Raman signatures, and are therefore important materials in the tar-
geted delivery of imaging agents and anticancer drugs [109]. Al-
though the placenta, lung, gastrointestinal tract and skin have been
cited as barriers to many nanomaterials, there is some evidence that
nanoparticles could translocate them [110]. Bhabra et al. [111] de-
scribed how nanoparticles could cause DNA damage across a cellular
barrier. They used a barrier of BeWo cells, which were grown as a
monolayer on a transwell insert in order to model the placental trans-
port of amino acids, immunoglobulin, hormones, fatty acids, transfer-
rin and viruses [112]. CoCr nanoparticles damage mitochondria [113]
and cobalt ions mimic hypoxic conditions [114] in the top layer of the
BeWo barrier, both cause ATP release from BeWo cells through Cx43
hemichannels and pannexin-1 channels. The released ATP activated
P2Y receptors in the second cellular layer, or passed through con-
nexin gap junctions into the second layer of cells. Here, ATP caused
a rise in intracellular calcium and subsequent ATP secretion, via con-
nexin hemichannels and pannexin channels. This ATP then will cause
DNA damage to human ﬁbroblasts beneath the barrier through
uncharacterized P2 receptor activation.
2.2. Pannexin channels activating P2 receptors
2.2.1. Immune cells: neutrophil chemotaxis and T cell activation
Pannexin-1 channels have been recently found to promote ATP re-
lease from several immune cell types [115] modulating different
physiological functions, such as neutrophil chemotaxis. Neutrophils
are activated by bacterial formylated peptides through formyl-
peptide receptors, and these receptors induce the release of ATP
through the opening of pannexin-1 channels. Released ATP activates
P2Y2 receptors amplifying and facilitating the signal to sense chemo-
tactic gradients. This allows neutrophils to polarize within the che-
motactic gradient ﬁeld and induce the translocation of pannexin-1,
ENTPD1 and adenosine A3 receptors to the leading edge of the cell.
Accumulation of these purinergic signaling components focuses ATP
release and the formation of adenosine at the leading edge, resulting
in an autocrine activation of A3 receptors, promoting cell migration
towards the source of formylated peptides [116]. Also C5a-induced
chemotaxis in murine macrophages was greatly modulated by auto-
crine ATP release activating P2Y2, P2Y12 and A3 receptor signaling,
but these purinergic responses were not reduced in macrophages de-
rived from pannexin-1-knockout mice, suggesting that pannexin-1
was not involved in ATP release in response to C5a [117].
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naling at the immune synapse could serve as a signal ampliﬁcation
mechanism needed for antigen recognition by T cells [115]. This pro-
cess involves the formation of an immune synapse between a T cell
and an antigen-presenting cell (APC). The immune synapse contains
a large number of signaling molecules that are required for T cell ac-
tivation, including MHC molecules, co-stimulatory receptors and T
cell receptors (TCR), in addition to the purinergic signaling receptors
P2X1, P2X4 and P2X7 [118]. Actually, it has been revealed that TCR
stimulation results in the translocation of P2X1, P2X4 and
pannexin-1 to the immune synapse [119] and triggers the release of
cellular ATP through pannexin-1 channels [120]. This ATP upon re-
lease into the immune synapse promotes a purinergic signal ampliﬁ-
cation through P2X1, P2X4 and P2X7 receptors in the T-cell,
facilitating a Ca2+ inﬂux and downstream signaling, leading to IL-2
transcription [119,121]. In this way, Woehrle et al. [122] recently
revealed that hypertonic saline resuscitation induced ATP release
through pannexin-1 channels and that P2X1, P2X4 and P2X7 receptor
activation enhanced T cell function. Extracellular ATP also regulates
numerous cellular immune responses, including differentiation of T-
helper cells [123] or B cell activation [124]. Extracellular ATP is also
indirectly involved in effector T cell suppression. ATP is converted to
adenosine by ectonucleotidases CD39 and CD73 which are expressed
on the surface of regulatory T cells, and this adenosine can activate
A2A receptor-mediated signaling processes to induce effector T-cell
suppression [125]. Nevertheless, the role of pannexin-1 or other
hemichannels in the production of this extracellular ATP has been
not established.
2.2.2. Apoptosis and “ﬁnd-me signals”
Apoptotic cells release ‘ﬁnd-me’ signals at the earliest stages of
death to recruit phagocytes. A recent study targeting pannexin-1
with pharmacological inhibitors or small interfering RNAs identiﬁed
pannexin-1 as the conduit for ATP release from apoptotic cells. Cleav-
age of pannexin-1 by the executioner caspases 3 and 7 appeared to
trigger its channel activity, and this was necessary for the recruitment
of phagocytic cells [126]. In the same way, dying cells deﬁcient in
pannexin-1 were less effective at recruiting macrophages in a trans-
well assay [127]. ATP itself, when released from injured cells, has
been reported to promote chemotactic and phagocytic responses in
microglia through P2Y12, P2Y13 and P2Y6 receptors [128]. Similar ob-
servations were reported for monocytes and dendritic cells [129]. It is
possible that ATP increases random migration of some of these cell
types rather than promoting chemotaxis. The receptor may be re-
quired for autocrine purinergic signaling that regulates chemotaxis
in response to other stimuli, for example to chemoattractive peptides
(as reviewed in Section 2.2.1) or to danger and pathogen associated
signals (DAMPs and PAMPs) that are present at inﬂammatory sites.
ATP and other danger signals may also induce the release of chemo-
kines from sentinel cells, such as IL-8, that can recruit leukocytes to
the inﬂammatory sites [130]. Thus, it seems more likely that released
ATP regulates chemotaxis rather than inducing it [115]. On the other
hand, ATP released through pannexin-1 as “ﬁnd-me” signal could be
related with anti-tumor immunity, as dying tumor cells can activate
NLRP3/inﬂammasome-dependent signaling in tumor associated mac-
rophages and promotes anti-tumor immunity [131].
2.2.3. Airway epithelial cells: mucociliary clearance
The mucociliary clearance process removes foreign particles and
pathogens from the airways and is the primary innate defense mech-
anism in the lung [132]. ATP within the airway surface liquid controls
key components of mucociliary clearance via activation of epithelial
cell surface purinergic receptors [133]. It has been described that
pannexin-1 channels account for 60% of the ATP released from airway
epithelial cells in response to cell swelling and membrane stretch
after hypotonic shock by a Rho-regulated pathway [134,135].Extracellular ATP activates P2Y2 receptors promoting mucin secre-
tion, increased ciliary beat frequency, and also regulating electrolyte
transport and airway surface liquid volume production by inhibiting
sodium absorption [136]. Therefore, pannexin-1 induced extracellular
ATP release promotes the cystic ﬁbrosis transmembrane conductance
regulator and Ca2+-activated Cl− channel activity [137].
2.2.4. HIV-1 infection
Seror et al. [138] revealed a novel signaling pathway involved in
the early steps of HIV-1 infection. Binding of the HIV-1 envelope to
cellular receptors leads to a rapid ATP release from host cells through
pannexin-1. ATP then activates P2Y2 receptors leading to phosphory-
lation and activation of Pyk2 kinase. P2Y2 and Pyk2 control plasma
membrane depolarization, hemifusion and fusion, which are required
steps for HIV-1 infection. Furthermore, pannexin-1, P2Y2, and Pyk2
were all recruited to the contact site between the HIV-encoded enve-
lope glycoprotein complex and CD4/CXCR4-containing membranes,
suggesting that they act within the virological synapse to transduce
signals that enhance membrane-to-membrane fusion, participating
in the infectious process, and facilitating the viral cell-to-cell trans-
mission [139]. P2Y2 activation is known to mediate Ca2+mobilization
via PLC [11] and Pyk2 detected during HIV-1 infection might be in-
duced in response to chemokine stimulation or elevations of intracel-
lular Ca2+ concentrations [140]. Potential inhibition of any of the
constituents of the molecular cascade of pannexin-1-ATP release-
P2Y2-Pyk2 could interrupt the HIV-1 life cycle at the level of viral
entry and could constitute effective novel strategies for the blockade
of HIV-1 infection.
2.2.5. Taste buds: transmission of taste information
Another example of physiological pannexin-1 derived purinergic
signaling can be observed in the taste bud type II receptor cells
[141] and in intact taste buds transmitting taste information [142].
The binding of sapid molecules to G-protein coupled gustatory recep-
tors leads to an increase of intracellular calcium, which can trigger the
opening of the non-selective monovalent cation channel TRPM5. This
pathway results in Na+ inﬂux and membrane depolarization, which
induces pannexin-1 channel opening and ATP release, activating
downstream purinergic ATP-signaling events [143]. Released ATP
will act on P2X receptors of the pre-synaptic serotonergic nerve
(Type III) cells, producing the release of serotonin at the pre-
synaptic membrane of these cells [144]. Serotonin will activate sero-
tonin receptors on the post-synaptic gustatory nerve ﬁber cells and
modulate the transmission of taste information to the brain. ATP acti-
vates P2X2 and P2X3 receptors of the post-synaptic gustatory nerve
ﬁbers from the facial glossopharyngeal nerves [145]. In addition, a
form of ampliﬁcation loop exists where ATP and its degradation prod-
uct, ADP, exert a positive feedback on the receptor cells (Type II)
through P2Y1 receptor activation, which mediates autocrine excita-
tion [146].
2.2.6. Erythrocytes: local blood-ﬂow regulation
It has been suggested that pannexin-1 channels could be involved
in local blood-ﬂow regulation [147]. Oxygen-deprived or shear-
stressed erythrocytes release ATP, which then binds to P2Y receptors
on erythrocytes and endothelial cells. In erythrocytes, activation of
the P2Y receptor leads to further release of ATP through pannexin-1
channels (ATP-inducing ATP release, Fig. 2). In endothelial cells, bind-
ing of ATP to P2Y receptors initiates a calcium wave propagated by
opening pannexin-1 channels. The calcium wave propagates back-
wards and reaches the precapillary sphincter region, where endothe-
lial nitric oxide (NO) synthase is activated, and NO released from the
endothelial cell relaxes the smooth muscle. In arterioles, smooth
muscle covers the endothelial cells and NO-induced relaxation of
smooth muscle could occur without the need of a propagated calcium
wave.
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tion of cis- and trans-epoxyeicosatrienoic acid (EET) from erythro-
cytes [148]. These vaso-active lipid mediators are metabolized from
arachidonic acid and released by an ATP-dependent stimulation of
erythrocyte P2X7 receptors. These actions require the presence of
functional channels such as the cystic ﬁbrosis transmembrane con-
ductance regulator and pannexin-1.
2.2.7. Retina: glaucoma
Increased ocular pressure resulting from acute glaucoma leads to
an elevation in extracellular ATP levels that damage the ganglion
cells. This theory is strongly supported by the ability of the soluble
ATPase apyrase and P2X7 receptor antagonists to reduce the ganglion
cell damage induced by acute elevations in ocular pressure [149]. The
demonstration that stimulation of the P2X7 receptor on retinal gan-
glion cells elevates intracellular calcium and kills retinal ganglion
cells in vitro is also consistent with this model [150]. The rise in ATP
is not due to cell rupture, while the pharmacology suggests that
pannexin-1 channels contribute to some of the ATP release. The pres-
ence of a pressure-dependent rise in extracellular ATP in the inner
retina provides further evidence that ATP release can transduce me-
chanical stimuli into neurochemical signals [151].
2.2.8. Ciliary epithelial cells: eye aqueous humor formation
Hypotonicity triggers ATP release by retinal non-pigmented (NPE)
and pigmented (PE) ciliary epithelial cells through pannexin-1 chan-
nels and connexin hemichannels in a similar proportion [152]. ATP
release enables the purinergic regulation of aqueous humor forma-
tion, controlling the ﬂuid inﬂow from the stroma through the
bilayered ciliary epithelium into the aqueous humor [152]. Chloride-
channel activity at the stromal and aqueous humor surfaces of the cil-
iary epitheliummay be of particular importance in modulating inﬂow
[153]. Stimulation of NPE chloride channels at the aqueous humor
surface is expected to increase inﬂow and intraocular pressure,
whereas stimulation of PE chloride channels at the contralateral sur-
face should have the opposite effect, reducing net ﬂuid inﬂow and
pressure [152]. Extracellular ATP acts directly on P2Y2 receptors of
the PE cells [154] to increase intracellular cAMP production which
augments PE-cell maxi-chloride channels activity [155]. At the con-
tralateral ciliary epithelial surface, ATP is metabolized to adenosine
by ectoenzymes and can activate adenosine A3 receptors of the NPE
cells, stimulating chloride channels and ﬂuid secretion [156].
2.2.9. Pituitary gland
In the pituitary gland, pannexin-1 mediates the release of ATP
from the terminals of magnocellular hypothalamic neurons and
other cells of the anterior pituitary [157]. In the anterior pituitary,
pannexin-1 expression has been identiﬁed in corticotrophic and a
fraction of somatotrophic cells, while in the posterior pituitary it has
been localized to S100-positive pituicytes. Pannexin-1 expression
has also been demonstrated in a mouse pituitary adrenocorticotropin
secreting cell line (AtT-20) and in rat immortalized pituitary cells
[158,159]. Overexpression of pannexin-1 in cultured pituitary cells
increased ATP release under normal and hypotonic experimental con-
ditions, while ATP release was blocked by carbenoxolone [159]. Fur-
thermore, ATP release was attenuated by two novel isoforms of
pannexin-1 (pannexin-1c and 1d) when co-expressed with full
length pannexin-1 [160]. These results suggest that the pannexin-1c
and 1d isoforms may act as dominant-negative effectors modulating
the function of full length pannexin-1 through the formation of het-
eromeric channels [160]. ATP released through pannexin-1 activates
P2X receptors in secretory anterior pituitary cells [158] and nerve ter-
minals in the posterior pituitary [161], molecular evidence is indica-
tive of P2X2, P2X3, P2X4, and P2X7 expression in this region [162].
Electrophysiological studies have established the expression of
P2X2 receptors in vasopressinergic neurohypophysial terminals andgonadotrophs [163,164]. These receptors facilitate the ﬁring of action
potentials, elevate intracellular Ca2+, and stimulate hormone release.
Similarly, P2Y receptors, including P2Y1 and P2Y2, have been de-
scribed in different cell populations of the pituitary gland and in the
majority of pituicytes in primary culture [162]. In the pituicytes, ATP
triggers a rapid rise in intracellular Ca2+, which was abolished
when PLC and the endoplasmic reticulum calcium pump were
blocked, indicating the functional operation of Ca2+-mobilizing P2Y
receptors [165].
2.2.10. Skeletal muscle: muscle physiology
ATP released during skeletal muscle activity through pannexin-1
channels, act through P2X and P2Y receptors to modulate Ca2+ ho-
meostasis in muscle cells and muscle physiology [166]. ATP-induced
activation of P2X receptors leads to an early increase in intracellular
Ca2+ which is linked to excitation–contraction cell coupling, while
ATP-induced activation of P2Y receptors leads to second, slow and
more gradual increase in intracellular Ca2+, which is linked to excita-
tion–transcription regulation [167].
3. Purinergic receptors modulating hemichannels activity
For over three decades it has been known that extracellular ATP is
able to permeabilize plasma membranes of cells to molecules up to
900 Da [168,169].We now know that ATP acts on purinergic receptors
to activate different signaling cascades some of which culminate in the
opening of hemichannels [73,170–173] (Fig. 2). The opening of hemi-
channels constitutes a direct route for cell permeabilization to dif-
ferent metabolites, which could ﬂux inside or outside the cell
depending on their concentration gradient, size, charge and structure
[63,172]. Activation of the P2X7 receptor activation is uniquely associ-
atedwith permeabilization of plasmamembranes, and is currently the
most well studied purinergic receptor associated with plasma mem-
brane hemichannels [37,73,170]. However, under some conditions
other purinergic receptors such as different P2Y or P2X receptors,
could also couple to the opening of plasma membrane hemichannels.
3.1. P2X7 receptors and hemichannels
Before the P2X7 receptor was cloned in 1996 [174], it was known as
the P2Z receptor. The most striking and unique feature of this receptor
was that activation led to a rapid uptake of higher molecular weight
molecules (up to approximately 900 Da). This cell permeabilization
process was considered to be due to the opening of a non-selective
“large pore”, in contrast to the small cationic conductance to Na+, K+
and Ca2+ formed by the receptor pore itself [37]. There are two con-
trasting and controversial hypotheses to explain this phenomenon.
One theory assumes that P2X7 receptor conductance pathways dilate
over the time, thereby allowing the passage of large molecules; the
other assumes that P2X7 receptors activate a second non-selective per-
meabilization pathway [37,170], although recent evidence points to a
co-existence of both processes [170] (Fig. 4). The ﬁrst attempt to char-
acterize the P2X7 receptor associated large pore was attributed to
Cx43, functioning as “half-gap junction” or pore connecting the cell cy-
toplasmwith the extracellular environment [175]. Cx43 expressionwas
found in J774 mouse macrophage cell line and extracellular ATP appli-
cationwas able to permeabilize this cell line, whereas it fails to permea-
bilize a cell line deﬁcient in Cx43 [175]. However, later it was
demonstrated that ATP induced cell permeabilization was due to P2Z
receptors and that macrophages from Cx43 deﬁcient mice exhibited
the same rate of cell permeabilization as the wild type counterparts
[176]. These early observations suggested that P2X7 receptor associated
pore had similarities with the connexin hemichannels. However, the
identity of P2X7 receptor associated non-selective, large-conductance
pore has remained uncharacterized until the recent identiﬁcation of
pannexin-1 channels as partial mediators for this dye uptake [177,178].
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Fig. 4. P2X7 receptor stimulation couple to different cell-permeation pathways. ATP binding to P2X7 receptor opens the ion channel pore within milliseconds. With the time ATP
allows the dilation of P2X7 receptor pore to a high conductance state permeable to NMDG. This new conformation of P2X7 receptor allows the opening of different hemichannel
pores usually measured through dye uptake experiments (reviewed on [170]). Opening of the different permeation pores allows diffusion of molecules from inside the cell to the
extracellular space and from the extracellular space to the intracellular space (represented as dotted arrows in the ﬁgure). Pannexin-1 channels are partially involved in P2X7 re-
ceptor induced cell permeabilization and are responsible for different downstream signaling events.
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P2X7 receptors (HEK293-P2X7) and in human THP-1 monocytes,
that the P2X7 receptor associated dye uptake was sensitive to carbe-
noxolone, a classical connexin gap-junction blocker which is more
potent inhibiting pannexin-1 channels than connexin hemichannels
[177]. Additional pharmacology found sensitivity to other pannexin-
1 channels blockers such as meﬂoquine and probenecid, but not for
classical connexin hemichannels blockers heptanol, lanthanum or
connexin-mimetic inhibitory peptides [177–181]. However, the use
of pharmacological inhibitors is inconclusive, since they also block
connexins and other channels; for example carbenoxolone blocks
voltage-gated calcium channels in the retina and decreased the ﬁring
rate in neuronal networks in response to a sustained depolarising
current [75,76]. In addition, some studies have found P2X7 receptor
induced dye uptake to be insensitive to carbenoxolone [182], al-
though this could be due to the fact that carbenoxolone is only effec-
tive at blocking the initial rapid dye uptake after P2X7 receptor
activation, without altering the ﬁnal accumulation of dye inside the
cell [73] and that both carbenoxolone and other drugs such as pro-
benecid lack efﬁcacy in inhibiting pannexin-1 when the potassium
channel subunit Kvβ3 was co-expressed [183].
Experiments in which endogenous knock-down of pannexin-1 ex-
pression using siRNA in human cell lines HEK293-P2X7, THP-1 mono-
cytes, 1321 N1 astrocytes and in mouse macrophage cell line J774,
revealed a decrease of the dye uptake associated to P2X7 receptor
stimulation [177–179]. The involvement of pannexin-1 is further sup-
ported by the use of a mimetic peptide identical to the ten amino acid
residues of the ﬁrst extracellular loop of human pannexin-1 close to
the ﬁrst transmembrane domain [177]. The use of small mimetic pep-
tides with homology to the extracellular loops of connexins has been
widely used to selectively characterize the involvement of different
connexins in the gap-junctions [184]. The mechanism of action ofthese peptides is unclear, presumably they selectively bind to the
docking site of two hemichannels and therefore interfere with the
hemichannel coupling in the gap-junction and permeation pore for-
mation [184]. However their speciﬁcity is also questioned and their
mechanism of action could be due to physical obstruction of the
pore of the hemichannel [185].
More evidences in favor of pannexin-1 mediating P2X7 dependent
dye uptake, comes from co-immunoprecipitation experiments, in
which P2X7 receptors can physically interact and associate with
pannexin-1 in the plasma membrane of cells. Overexpression of
pannexin-1 with P2X7 receptors resulted in larger ATP-induced in-
ward currents and dye uptake compared to cells expressing P2X7 re-
ceptor with endogenous levels of pannexin-1 [160,177,186]. All these
data support the role of pannexin-1 channels as part of the P2X7 re-
ceptor associated permeation conduit.
However, work from two independent groups showed that P2X7
receptor associated large-pore was more complicated than a single
permeation pathway and presented different selectivity for cationic
and anionic dyes [182,187]. In HEK293 cells expressing P2X7 recep-
tors, the associated dye uptake was only observed to cationic dyes,
such as Yo-Pro-1 or ethidium bromide. In contrast, in murine macro-
phages, P2X7 receptors activate at least two separate permeation
pathways, one mainly selective for cationic dyes and the other mainly
selective for anionic dyes, being the anionic pathway insensitive to
temperature and through a diffusional process [182,187]. This ties in
with previous studies which report two phases for P2X7 receptor me-
diated dye uptake in macrophages, where pannexin-1 was involved
in the ﬁrst fast phase (reviewed in [73]). However, in both of the
studies reporting the different ion selective permeation pathways as-
sociated with the P2X7 receptor, carbenoxolone or meﬂoquine were
ineffective in blocking cell permeabilization and pannexin-1 contri-
bution was discarded, proposing the involvement of a transporter or
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other independent works employing murine macrophages derived
from pannexin-1 knock-out mice, showed no alteration of P2X7 re-
ceptor associated dye uptake in macrophages, but both conﬁrmed
the involvement of pannexin-1 mediating ATP release [127,188].
From all these studies we can conclude that P2X7 receptor associat-
ed dye uptake is a cell-type selective process and a very complex
mechanism involving different permeation pathways with yet to be
identiﬁed hemichannels or pathways activated at different times
[170] (Fig. 4). As suggested by siRNA experiments and the use of
pannexin-1 knock-outmicewe can postulate that pannexin-1 channels
are predominantly associated with P2X7 receptor activation in human
cells more than in mouse macrophages. Unpublished data from our
group using primary macrophages from wild type and pannexin-1
knock-out mice also supports this idea since we found that (i) carbe-
noxolone had little effect blocking P2X7 receptor associated dye uptake
in primarymousemacrophages and (ii) macrophages from pannexin-1
knock-out mice present a strong dye uptake insensitive to carbenoxo-
lone. In agreement with previous studies [127,182], we hypothesize
that pannexin-1 is not the main permeation pathway in primary mu-
rine macrophages associated with P2X7 receptor activation. Macro-
phages derived from pannexin-1 knock-out mice present a strong
compensation effect in the P2X7 receptor dye uptake pathway insensi-
tive to carbenoxolone, probably due to the activation uncharacterized
permeation pathways. The ability of P2X7 receptor to couple to a non-
pannexin-1 dye uptake pathway in pannexin-1 knock outmacrophages
leads to a compensatory effect in the release of the pro-inﬂammatory
cytokine IL-1β [127]. This scenario could become even more complex
with the characterization of human pannexin-1 splice variants
[180,189] and the recent description of pannexin-1 dominant-
negative splice variants in rat pituitary cells [160].
3.2. Other P2X receptors and hemichannels
It has been described that in some conditions both P2X2 and P2X4
receptors can permeate the cell to large molecules [190–193]. Al-
though this permeation pathway is not fully characterized and its
molecular nature has not been elucidated, data so far support the
idea that the P2X ion pore dilates over the time due to a conforma-
tional change [190,194], similar to P2X7 receptor pore opening prop-
erties [170,195]. The involvement of pannexin-1 channels has been
questioned and pharmacological data shows that P2X2 induced dye
uptake was insensitive to carbenoxolone [190]. However, it has
been recently published that P2X2 receptors physically associate
with pannexin-1 [160], but the function of this association was not
further characterized. Also, P2X2 induced dye uptake shares some
similarities with the P2X7 receptor large permeation pathways and
both have been found as a separate permeation pathway sensitive
to colchicine [192].
In the absence of extracellular calcium, P2X4 receptor forms a
larger pore that allows permeability to big molecules including
NMDG, propidium iodide or ethidium bromide [191,196], but the
exact nature of this permeation pathway has not been elucidated
and therefore the involvement of hemichannels in this process is
mere speculation. However, P2X4 receptor homotrimmers have
been found to interact with P2X7 receptor homotrimmers and form
a functional association [197]. It would be interesting to evaluate if
this functional association could lead to alterations in the opening of
hemichannels activated by P2X7 receptors.
3.3. P2Y receptors and hemichannel activation
The generation of IP3 and the downstream intracellular calcium rise
is a signal to activate the opening of plasma membrane hemichannels
[64,198] (Fig. 2). While this mechanism is well characterized for differ-
ent connexin hemichannels, different studies present contradictorydata regarding pannexin-1 activation by intracellular calcium
[173,177,179,180]. While this contradiction could be due to the use of
different cell types and experimental conditions, it is clear that in
some cells, such as astrocytes, pannexin-1 channels are activated due
to IP3 and elevated intracellular calcium [99]. Purinergic P2Y receptors
induce an increase in intracellular calcium via IP3 formation (see
Section 1.3) [12]. Many studies have reported that P2Y dependent in-
crease in intracellular calcium is a directmechanism to open hemichan-
nels and propagate calcium waves in a variety of cells. It has been
reported that P2Y opens Cx43 hemichannels in retina epithelial cells
[199] and Cx32 hemichannels in bladder cancerous epithelial cells
[200]. P2Y2 and P2Y4 receptors mediated signaling lead to the opening
of Cx26 and Cx30 in cochlear epithelial cells [88], while in astrocytes
P2Y2 receptor mediates the opening of pannexin-1 channels and Cx43
hemichannels [99,201]. Astrocytic calcium signaling has received con-
siderable interest because of its role in brain function [202,203]. Origi-
nally, it was believed that inter-astrocytic signaling was mediated by
diffusion of IP3 and/or calcium across gap junctions, but increasing ob-
servations suggest that an extracellular pathway exists and calcium
waves can cross cell-free areas via ATP release evoking calcium incre-
ments in astrocytes physically isolated from the stimulated cell by acti-
vating P2Y receptors [204,205].
3.4. Pathophysiological implications of purinergic signaling activating
hemichannels
As described in Section 2, one of the main metabolites permeating
hemichannels is intracellular ATP, and therefore the opening of hemi-
channels after purinergic P2 receptors stimulation could be an auto-
crine or paracrine positive feedback loop to propagate or enhance
purinergic activation by increasing the release of ATP (Fig. 2). ATP-
induced ATP release is commonly inhibited by broad gap junction
blockers and is strongly implicated in the propagation of calcium
waves among astrocytes and epithelial/endothelia cells.
However, besides ATP, there are other metabolites that could per-
meate across hemichannels [63], and they could mediate some of the
physiological effects of purinergic receptor stimulation. For example,
it is reported that prostaglandin E2 can permeate through Cx43 hemi-
channels [206,207], and it has been recently found that P2X4 recep-
tors increase the release of prostaglandin E2 from macrophages and
contribute to pain sensation [208]. However as has been described,
it is not known whether P2X4 receptor can activate a hemichannel
(see Section 3.2). Prostaglandin E2 is also a strong mediator of fever
[209], and recently a study has demonstrated that P2X7 receptor as-
sociated dye uptake pathway was important for the development of
fever in a murine in vivo model induced after intraperitoneal admin-
istration of LPS and ATP [192]. Fever was reduced using colchicine,
which blocked P2X7 receptor associated dye uptake without affecting
the P2X7 channel itself, and although this study did not characterized
the production of prostaglandin after P2X7 receptor stimulation or if
colchicine was blocking an hemichannel permeation pathway [192],
it is tempting to speculate that P2X7 receptor stimulation of hemi-
channels could mediate the release of prostaglandin and enhance
fever.
The activation of hemichannel-like large pores associated with
P2X7 receptors is also involved in the activation of the inﬂammasome/
caspase-1 and the induction of cell death [73,177,210,211]. Acti-
vation of the inﬂammasome leads to the release of pro-inﬂammatory
cytokines of the IL-1 family, such as IL-1β and IL-18 [212]. P2X7 recep-
tors activating pannexin-1 channels and other permeation routes have
been implicated in this process, especially in human monocytes/
macrophages and the central nervous system (CNS). However, as
discussed in Section 3.1, dye uptake through other functional hemi-
channels could also compensate the lack of pannexin-1 as observed
in pannexin-1 deﬁcient mice [73,127,177,210,213]. However, the
exact signaling mechanism from cell permeabilization through
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could be that hemichannels opening causes an intracellular stress
which is sensed by the inﬂammasome and therefore the activation of
the inﬂammasome is a reparative response for such stress [214]. Pro-
longed cell permeabilization through activation of pannexin channels
and/or connexin hemichannels by ATP induces cell death in macro-
phages, astrocytes and neurons [73,178,213,215,216] and blocking
hemichannels could represent a novel and alternative strategy to re-
duce inﬂammation and neuronal loss in various pathological states.
4. Conclusions and future perspectives
The ﬁeld of the purinergic signaling is tightly coupled to both the
connexin and pannexin channels. There is a dual cross talk amongst
hemichannels and purinergic receptors: (i) hemichannels represent
an important pathway to control the release of ATP and other nucle-
otides, which are the agonists for purinergic receptors; and (ii) hemi-
channels are activated by different purinergic receptors, and mediate
the release of different metabolites from the cell. This association is
important to amplify purinergic signaling and to expand the down-
stream effects of purinergic receptors (Fig. 2).
Although the permeation of ATP through hemichannels and the
activation of the purinergic signaling are well characterized, we still
need to understand which other metabolites could permeate across
hemichannels activated by purinergic receptors. Hemichannels are
permeable to a wide range of small second messengers and mole-
cules, and the activation of hemichannels after purine receptors acti-
vation could be an important pathway to control the release and
uptake of different molecules. In that sense, they could be a pathway
to permeate the cell membrane to signaling amino acids such as as-
partate or glutamate, small RNA molecules or peptides, such as anti-
genic peptides or glutathione, or small bacterial endotoxins, such as
muramyl dipeptide, that could directly enter the cytosol of the mac-
rophage and activate intracellular pathogen sensing receptors
[217–222]. In this regard it has been recently reported that P2X7 re-
ceptor and pannexin-1 mediates the release of cardioprotectants in-
duced by ischemia in the heart [223]. The pathophysiological
implication of all these permeation pathways opens a new research
horizon for the purinergic signaling, but yet they bring out the impor-
tance of hemichannels as novel potential drug targets.
Acknowledgements
The authors are indebted to Dr. Christopher D. Keating for critical
revision of the manuscript. This work was supported by grants from
PN I+D+I 2008–2011-Instituto Salud Carlos III-FEDER (EMER07/
049 and PI09/0120), Fundación Séneca (11922/PI/09), managed by
Fundación Formación Investigación Sanitaria Región de Murcia (FFIS).
References
[1] A.N. Drury, A. Szent-Gyorgyi, The physiological activity of adenine compounds
with especial reference to their action upon the mammalian heart, J. Physiol.
68 (1929) 213–237.
[2] G. Burnstock, Purinergic nerves, Pharmacol. Rev. 24 (1972) 509–581.
[3] R.A. North, A. Verkhratsky, Purinergic transmission in the central nervous sys-
tem, Pﬂugers Arch. 452 (2006) 479–485.
[4] Y. Pankratov, U. Lalo, A. Verkhratsky, R.A. North, Vesicular release of ATP at cen-
tral synapses, Pﬂugers Arch. 452 (2006) 589–597.
[5] G. Burnstock, Physiology and pathophysiology of purinergic neurotransmission,
Physiol. Rev. 87 (2007) 659–797.
[6] M.P. Abbracchio, G. Burnstock, A. Verkhratsky, H. Zimmermann, Purinergic sig-
nalling in the nervous system: an overview, Trends Neurosci. 32 (2009) 19–29.
[7] G. Burnstock, Unresolved issues and controversies in purinergic signalling, J.
Physiol. 586 (2008) 3307–3312.
[8] H. Zimmermann, Ectonucleotidases in the nervous system, Novartis Found.
Symp. 276 (2006) 113–128 discussion 128–130, 233–117, 275–181.
[9] G. Burnstock, Purinergic receptors, J. Theor. Biol. 62 (1976) 491–503.
[10] G. Burnstock, C. Kennedy, Is there a basis for distinguishing two types of
P2-purinoceptor? Gen. Pharmacol. 16 (1985) 433–440.[11] V. Ralevic, G. Burnstock, Receptors for purines and pyrimidines, Pharmacol. Rev.
50 (1998) 413–492.
[12] M.P. Abbracchio, G. Burnstock, J.M. Boeynaems, E.A. Barnard, J.L. Boyer, C. Kennedy,
G.E. Knight, M. Fumagalli, C. Gachet, K.A. Jacobson, G.A. Weisman, International
Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide re-
ceptors: frommolecular mechanisms and pathophysiology to therapy, Pharmacol.
Rev. 58 (2006) 281–341.
[13] G. Burnstock, Purine and pyrimidine receptors, Cell. Mol. Life Sci. 64 (2007)
1471–1483.
[14] S.J. Fountain, K. Parkinson, M.T. Young, L. Cao, C.R.L. Thompson, R.A. North, An
intracellular P2X receptor required for osmoregulation in Dictyostelium discoi-
deum, Nature 448 (2007) 200–203.
[15] S.J. Fountain, G. Burnstock, An evolutionary history of P2X receptors, Purinergic
Signal. 5 (2009) 269–272.
[16] G. Burnstock, G.E. Knight, Cellular distribution and functions of P2 receptor sub-
types in different systems, Int. Rev. Cytol. 240 (2004) 31–304.
[17] G. Burnstock, Pathophysiology and therapeutic potential of purinergic signaling,
Pharmacol. Rev. 58 (2006) 58–86.
[18] M.P. Abbracchio, G. Burnstock, Purinergic signalling: pathophysiological roles,
Jpn. J. Pharmacol. 78 (1998) 113–145.
[19] G. Burnstock, Purinergic signaling and vascular cell proliferation and death,
Arterioscler. Thromb. Vasc. Biol. 22 (2002) 364–373.
[20] F. Libert, M. Parmentier, A. Lefort, C. Dinsart, J. Van Sande, C.Maenhaut,M.J. Simons,
J.E. Dumont, G. Vassart, Selective ampliﬁcation and cloning of four newmembers of
the G protein-coupled receptor family, Science 244 (1989) 569–572.
[21] Q.Y. Zhou, C. Li, M.E. Olah, R.A. Johnson, G.L. Stiles, O. Civelli, Molecular cloning
and characterization of an adenosine receptor: the A3 adenosine receptor,
Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 7432–7436.
[22] B.B. Fredholm, I.J. AP, K.A. Jacobson, K.N. Klotz, J. Linden, International Union of
Pharmacology. XXV. Nomenclature and classiﬁcation of adenosine receptors,
Pharmacol. Rev. 53 (2001) 527–552.
[23] M.E. Olah, G.L. Stiles, The role of receptor structure in determining adenosine re-
ceptor activity, Pharmacol. Ther. 85 (2000) 55–75.
[24] B.R. Cobb, L. Fan, T.E. Kovacs, E.J. Sorscher, J.P. Clancy, Adenosine receptors and
phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells, Am. J.
Respir. Cell Mol. Biol. 29 (2003) 410–418.
[25] R. Yaar, M.R. Jones, J.F. Chen, K. Ravid, Animal models for the study of adenosine
receptor function, J. Cell. Physiol. 202 (2005) 9–20.
[26] S. Alexander, A. Mathie, J. Peters, Guide to receptors and channels (GRAC), 4th
edition, Br. J. Pharmacol. 158 (Suppl 1) (2009) S1–S254.
[27] F. Xu, H.Wu, V. Katritch, G.W.Han, K.A. Jacobson, Z.G. Gao, V. Cherezov, R.C. Stevens,
Structure of an agonist-bound human A2A adenosine receptor, Science 332 (2011)
322–327.
[28] S.J. Reshkin, L. Guerra, A. Bagorda, L. Debellis, R. Cardone, A.H. Li, K.A. Jacobson,
V. Casavola, Activation of A(3) adenosine receptor induces calcium entry and
chloride secretion in A(6) cells, J. Membr. Biol. 178 (2000) 103–113.
[29] K.D. Lustig, A.K. Shiau, A.J. Brake, D. Julius, Expression cloning of an ATP receptor
from mouse neuroblastoma cells, Proc. Natl. Acad. Sci. U. S. A. 90 (1993)
5113–5117.
[30] T.E. Webb, J. Simon, B.J. Krishek, A.N. Bateson, T.G. Smart, B.F. King, G. Burnstock,
E.A. Barnard, Cloning and functional expression of a brain G-protein-coupled
ATP receptor, FEBS Lett. 324 (1993) 219–225.
[31] M.P. Abbracchio, J.-M. Boeynaems, E.A. Barnard, J.L. Boyer, C. Kennedy, M.T. Miras-
Portugal, B.F. King, C. Gachet, K.A. Jacobson, G.A. Weisman, G. Burnstock,
Characterization of the UDP-glucose receptor (re-named here the P2Y14 recep-
tor) adds diversity to the P2Y receptor family, Trends Pharmacol. Sci. 24 (2003)
52–55.
[32] H. Inbe, S. Watanabe, M. Miyawaki, E. Tanabe, J.A. Encinas, Identiﬁcation and
characterization of a cell-surface receptor, P2Y15, for AMP and adenosine, J.
Biol. Chem. 279 (2004) 19790–19799.
[33] L. Erb, R. Garrad, Y. Wang, T. Quinn, J.T. Turner, G.A. Weisman, Site-directed mu-
tagenesis of P2U purinoceptors. Positively charged amino acids in transmem-
brane helices 6 and 7 affect agonist potency and speciﬁcity, J. Biol. Chem. 270
(1995) 4185–4188.
[34] Q. Jiang, D. Guo, B.X. Lee, A.M. Van Rhee, Y.C. Kim, R.A. Nicholas, J.B. Schachter,
T.K. Harden, K.A. Jacobson, A mutational analysis of residues essential for ligand
recognition at the human P2Y1 receptor, Mol. Pharmacol. 52 (1997) 499–507.
[35] C. Hoffmann, S. Moro, R.A. Nicholas, T.K. Harden, K.A. Jacobson, The role of amino
acids in extracellular loops of the human P2Y1 receptor in surface expression
and activation processes, J. Biol. Chem. 274 (1999) 14639–14647.
[36] I. von Kugelgen, Pharmacological proﬁles of cloned mammalian P2Y-receptor
subtypes, Pharmacol. Ther. 110 (2006) 415–432.
[37] R.A. North, Molecular physiology of P2X receptors, Physiol. Rev. 82 (2002)
1013–1067.
[38] A.J. Brake, M.J. Wagenbach, D. Julius, New structural motif for ligand-gated ion
channels deﬁned by an ionotropic ATP receptor, Nature 371 (1994) 519–523.
[39] S. Valera, N. Hussy, R.J. Evans, N. Adami, R.A. North, A. Surprenant, G. Buell, A
new class of ligand-gated ion channel deﬁned by P2x receptor for extracellular
ATP, Nature 371 (1994) 516–519.
[40] A. Surprenant, R.A. North, Signaling at purinergic P2X receptors, Annu. Rev. Phy-
siol. 71 (2009) 333–359.
[41] S.S. Stojilkovic, M. Tomic, M.L. He, Z. Yan, T.A. Koshimizu, H. Zemkova, Molecular
dissection of purinergic P2X receptor channels, Ann. N. Y. Acad. Sci. 1048 (2005)
116–130.
[42] T.M. Egan, D.S. Samways, Z. Li, Biophysics of P2X receptors, Pﬂugers Arch. 452
(2006) 501–512.
90 A. Baroja-Mazo et al. / Biochimica et Biophysica Acta 1828 (2013) 79–93[43] J.A. Roberts, C. Vial, H.R. Digby, K.C. Agboh, H. Wen, A. Atterbury-Thomas, R.J.
Evans, Molecular properties of P2X receptors, Pﬂugers Arch. 452 (2006)
486–500.
[44] T. Kawate, J.C. Michel, W.T. Birdsong, E. Gouaux, Crystal structure of the
ATP-gated P2X(4) ion channel in the closed state, Nature 460 (2009) 592–598.
[45] K.J. Lynch, E. Touma, W. Niforatos, K.L. Kage, E.C. Burgard, T. van Biesen, E.A.
Kowaluk, M.F. Jarvis, Molecular and functional characterization of human
P2X(2) receptors, Mol. Pharmacol. 56 (1999) 1171–1181.
[46] C. Coddou, Z. Yan, T. Obsil, J.P. Huidobro-Toro, S.S. Stojilkovic, Activation and
regulation of purinergic P2X receptor channels, Pharmacol. Rev. 63 (2011)
641–683.
[47] C. Lewis, S. Neidhart, C. Holy, R.A. North, G. Buell, A. Surprenant, Coexpression of
P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory
neurons, Nature 377 (1995) 432–435.
[48] F. Soto, M. Garcia-Guzman, J.M. Gomez-Hernandez, M. Hollmann, C. Karschin,
W. Stuhmer, P2X4: an ATP-activated ionotropic receptor cloned from rat brain,
Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 3684–3688.
[49] A. Nicke, D. Kerschensteiner, F. Soto, Biochemical and functional evidence for
heteromeric assembly of P2X1 and P2X4 subunits, J. Neurochem. 92 (2005)
925–933.
[50] B.S. Gan, E. Krump, L.D. Shrode, S. Grinstein, Loading pyranine via purinergic re-
ceptors or hypotonic stress for measurement of cytosolic pH by imaging, Am. J.
Physiol. 275 (1998) C1158–C1166.
[51] C. Virginio, A.MacKenzie, R.A. North, A. Surprenant, Kinetics of cell lysis, dye uptake
and permeability changes in cells expressing the rat P2X7 receptor, J. Physiol. 519
(Pt 2) (1999) 335–346.
[52] S. Roger, P. Pelegrin, A. Surprenant, Facilitation of P2X7 receptor currents and
membrane blebbing via constitutive and dynamic calmodulin binding, J. Neu-
rosci. 28 (2008) 6393–6401.
[53] P. Pelegrin, Targeting interleukin-1 signaling in chronic inﬂammation: focus on
P2X(7) receptor and pannexin-1, Drug News Perspect. 21 (2008) 424–433.
[54] S.G. Brown, A. Townsend-Nicholson, K.A. Jacobson, G. Burnstock, B.F. King, Het-
eromultimeric P2X(1/2) receptors show a novel sensitivity to extracellular pH, J.
Pharmacol. Exp. Ther. 300 (2002) 673–680.
[55] A. Aschraﬁ, S. Sadtler, C. Niculescu, J. Rettinger, G. Schmalzing, Trimeric architec-
ture of homomeric P2X2 and heteromeric P2X1+2 receptor subtypes, J. Mol.
Biol. 342 (2004) 333–343.
[56] J.A. Calvert, R.J. Evans, Heterogeneity of P2X receptors in sympathetic neurons:
contribution of neuronal P2X1 receptors revealed using knockout mice, Mol.
Pharmacol. 65 (2004) 139–148.
[57] V. Spelta, L.H. Jiang, A. Surprenant, R.A. North, Kinetics of antagonist actions at
rat P2X2/3 heteromeric receptors, Br. J. Pharmacol. 135 (2002) 1524–1530.
[58] V. Spelta, A. Mekhalﬁa, D. Rejman, M. Thompson, G.M. Blackburn, R.A. North,
ATP analogues with modiﬁed phosphate chains and their selectivity for rat
P2X2 and P2X2/3 receptors, Br. J. Pharmacol. 140 (2003) 1027–1034.
[59] A. Surprenant, D.A. Schneider, H.L. Wilson, J.J. Galligan, R.A. North, Functional
properties of heteromeric P2X(1/5) receptors expressed in HEK cells and excit-
atory junction potentials in guinea-pig submucosal arterioles, J. Auton. Nerv.
Syst. 81 (2000) 249–263.
[60] J. O'Brien, R. Bruzzone, T.W. White, M.R. Al-Ubaidi, H. Ripps, Cloning and expres-
sion of two related connexins from the perch retina deﬁne a distinct subgroup of
the connexin family, J. Neurosci. 18 (1998) 7625–7637.
[61] L. Ebihara, New roles for connexons, News Physiol. Sci. 18 (2003) 100–103.
[62] M.V. Bennett, J.E. Contreras, F.F. Bukauskas, J.C. Saez, New roles for astrocytes:
gap junction hemichannels have something to communicate, Trends Neurosci.
26 (2003) 610–617.
[63] A.L. Harris, Connexin channel permeability to cytoplasmic molecules, Prog. Bio-
phys. Mol. Biol. 94 (2007) 120–143.
[64] E. De Vuyst, E. Decrock, L. Cabooter, G.R. Dubyak, C.C. Naus,W.H. Evans, L. Leybaert,
Intracellular calcium changes trigger connexin 32 hemichannel opening, EMBO J.
25 (2006) 34–44.
[65] H.K. Eltzschig, T. Eckle, A. Mager, N. Kuper, C. Karcher, T. Weissmuller, K. Boengler,
R. Schulz, S.C. Robson, S.P. Colgan, ATP release from activatedneutrophils occurs via
connexin 43 and modulates adenosine-dependent endothelial cell function, Circ.
Res. 99 (2006) 1100–1108.
[66] S. Sonntag, G. Söhl, R. Dobrowolski, J. Zhang, M. Theis, E. Winterhager, F.F.
Bukauskas, K. Willecke, Mouse lens connexin23 (Gje1) does not form functional
gap junction channels but causes enhanced ATP release from HeLa cells, Eur. J.
Cell Biol. 88 (2009) 65–77.
[67] H.B. Zhao, Gap junctional hemichannel-mediated ATP release and hearing con-
trols in the inner ear, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18724–18729.
[68] C. D'Hondt, R. Ponsaerts, H. De Smedt, M. Vinken, E. De Vuyst, M. De Bock, N.
Wang, V. Rogiers, L. Leybaert, B. Himpens, G. Bultynck, Pannexin channels in
ATP release and beyond: an unexpected rendezvous at the endoplasmic reticu-
lum, Cell. Signal. 23 (2011) 305–316.
[69] R. Bruzzone, S.G. Hormuzdi, M.T. Barbe, A. Herb, H. Monyer, Pannexins, a family
of gap junction proteins expressed in brain, Proc. Natl. Acad. Sci. U. S. A. 100
(2003) 13644–13649.
[70] B.A. MacVicar, R.J. Thompson, Non-junction functions of pannexin-1 channels,
Trends Neurosci. 33 (2010) 93–102.
[71] J.L. Gordon, Extracellular ATP: effects, sources and fate, Biochem. J. 233 (1986)
309–319.
[72] G. Burnstock, Purinergic signalling: past, present and future, Braz. J. Med. Biol.
Res. 42 (2009) 3–8.
[73] P. Pelegrin, A. Surprenant, The P2X(7) receptor-pannexin connection to dye up-
take and IL-1beta release, Purinergic Signal. 5 (2009) 129–137.[74] L. Bao, S. Locovei, G. Dahl, Pannexin membrane channels are mechanosensitive
conduits for ATP, FEBS Lett. 572 (2004) 65–68.
[75] N. Rouach, M. Segal, A. Koulakoff, C. Giaume, E. Avignone, Carbenoxolone block-
ade of neuronal network activity in culture is not mediated by an action on gap
junctions, J. Physiol. 553 (2003) 729–745.
[76] J.P. Vessey, M.R. Lalonde, H.A. Mizan, N.C. Welch, M.E.M. Kelly, S. Barnes, Carbe-
noxolone inhibition of voltage-gated Ca channels and synaptic transmission in
the retina, J. Neurophysiol. 92 (2004) 1252–1256.
[77] C.W. Lo, Genes, gene knockouts, and mutations in the analysis of gap junctions,
Dev. Genet. 24 (1999) 1–4.
[78] F. Cao, R. Eckert, C. Elfgang, J.M. Nitsche, S.A. Snyder, D.F. Hülser, K. Willecke, B.J.
Nicholson, A quantitative analysis of connexin-speciﬁc permeability differences
of gap junctions expressed in HeLa transfectants and Xenopus oocytes, J. Cell Sci.
111 (Pt 1) (1998) 31–43.
[79] R.D. Veenstra, H.Z. Wang, D.A. Beblo, M.G. Chilton, A.L. Harris, E.C. Beyer, P.R.
Brink, Selectivity of connexin-speciﬁc gap junctions does not correlate with
channel conductance, Circ. Res. 77 (1995) 1156–1165.
[80] P. Gomes, S.P. Srinivas, W. Van Driessche, J. Vereecke, B. Himpens, ATP release
through connexin hemichannels in corneal endothelial cells, Invest. Ophthal-
mol. Vis. Sci. 46 (2005) 1208–1218.
[81] J. Mohay, B.J. McLaughlin, Corneal endothelial wound repair in normal and mitoti-
cally inhibited cultures, Graefes Arch. Clin. Exp. Ophthalmol. 233 (1995) 727–736.
[82] K. Williams, M. Watsky, Gap junctional communication in the human corneal
endothelium and epithelium, Curr. Eye Res. 25 (2002) 29–36.
[83] P. Gomes, S.P. Srinivas, J. Vereecke, B. Himpens, ATP-dependent paracrine inter-
cellular communication in cultured bovine corneal endothelial cells, Invest.
Ophthalmol. Vis. Sci. 46 (2005) 104–113.
[84] R. Nobili, F. Mammano, Biophysics of the cochlea. II: stationary nonlinear phe-
nomenology, J. Acoust. Soc. Am. 99 (1996) 2244–2255.
[85] G.D. Housley, D. Greenwood, J.F. Ashmore, Localization of cholinergic and puri-
nergic receptors on outer hair cells isolated from the guinea-pig cochlea, Proc.
Biol. Sci. 249 (1992) 265–273.
[86] M.A. Crumling, M. Tong, K.L. Aschenbach, L.Q. Liu, C.M. Pipitone, R.K. Duncan,
P2X antagonists inhibit styryl dye entry into hair cells, Neuroscience 161
(2009) 1144–1153.
[87] M. Lahne, J.E. Gale, Damage-induced activation of ERK1/2 in cochlear supporting
cells is a hair cell death-promoting signal that depends on extracellular ATP and
calcium, J. Neurosci. 28 (2008) 4918–4928.
[88] P. Majumder, G. Crispino, L. Rodriguez, C.D. Ciubotaru, F. Anselmi, V. Piazza, M.
Bortolozzi, F. Mammano, ATP-mediated cell-cell signaling in the organ of
Corti: the role of connexin channels, Purinergic Signal. 6 (2010) 167–187.
[89] R.D. Graff, E.R. Lazarowski, A.J. Banes, G.M. Lee, ATP release by mechanically
loaded porcine chondrons in pellet culture, Arthritis Rheum. 43 (2000)
1571–1579.
[90] H.A. Praetorius, K.R. Spring, Bending the MDCK cell primary cilium increases in-
tracellular calcium, J. Membr. Biol. 184 (2001) 71–79.
[91] M.M. Knight, S.R. McGlashan, M. Garcia, C.G. Jensen, C.A. Poole, Articular chon-
drocytes express connexin 43 hemichannels and P2 receptors — a putative
mechanoreceptor complex involving the primary cilium? J. Anat. 214 (2009)
275–283.
[92] D.A. Lee, T. Noguchi, M.M. Knight, L. O'Donnell, G. Bentley, D.L. Bader, Response
of chondrocyte subpopulations cultured within unloaded and loaded agarose, J.
Orthop. Res. 16 (1998) 726–733.
[93] E.E. Tansey, K.F. Kwaku, P.E. Hammer, D.B. Cowan, M. Federman, S. Levitsky, J.D.
McCully, Reduction and redistribution of gap and adherens junction proteins
after ischemia and reperfusion, Ann. Thorac. Surg. 82 (2006) 1472–1479.
[94] S.R. Bond, A. Lau, S. Penuela, A.V. Sampaio, T.M. Underhill, D.W. Laird, C.C. Naus,
Pannexin 3 is a novel target for Runx2, expressed by osteoblasts and mature
growth plate chondrocytes, J. Bone Miner. Res. 26 (2011) 2911–2922.
[95] T. Iwamoto, T. Nakamura, A. Doyle, M. Ishikawa, S. de Vega, S. Fukumoto, Y.
Yamada, Pannexin 3 regulates intracellular ATP/cAMP levels and promotes
chondrocyte differentiation, J. Biol. Chem. 285 (2010) 18948–18958.
[96] M.K. Elfervig, R.D. Graff, G.M. Lee, S.S. Kelley, A. Sood, A.J. Banes, ATP induces
Ca(2+) signaling in human chondrons cultured in three-dimensional agarose
ﬁlms, Osteoarthr. Cartil. 9 (2001) 518–526.
[97] B. Pingguan-Murphy, M. El-Azzeh, D.L. Bader, M.M. Knight, Cyclic compression
of chondrocytes modulates a purinergic calcium signalling pathway in a strain
rate- and frequency-dependent manner, J. Cell. Physiol. 209 (2006) 389–397.
[98] R. Dermietzel, Y. Gao, E. Scemes, D. Vieira, M. Urban, M. Kremer, M.V. Bennett,
D.C. Spray, Connexin43 null mice reveal that astrocytes express multiple con-
nexins, Brain Res. Brain Res. Rev. 32 (2000) 45–56.
[99] R. Iglesias, G. Dahl, F. Qiu, D.C. Spray, E. Scemes, Pannexin 1: the molecular sub-
strate of astrocyte “hemichannels”, J. Neurosci. 29 (2009) 7092–7097.
[100] J. Reyes, C. Hernández-Carballo, G. Pérez-Flores, P. Pérez-Cornejo, J. Arreola, Lack
of coupling between membrane stretching and pannexin-1 hemichannels, Bio-
chem. Biophys. Res. Commun. 380 (2009) 50–53.
[101] J.T. Neary, Y. Kang, K.A. Willoughby, E.F. Ellis, Activation of extracellular
signal-regulated kinase by stretch-induced injury in astrocytes involves extra-
cellular ATP and P2 purinergic receptors, J. Neurosci. 23 (2003) 2348–2356.
[102] X. Wang, G. Arcuino, T. Takano, J. Lin, W.G. Peng, P. Wan, P. Li, Q. Xu, Q.S. Liu, S.A.
Goldman, M. Nedergaard, P2X7 receptor inhibition improves recovery after spi-
nal cord injury, Nat. Med. 10 (2004) 821–827.
[103] A.C. Brisset, B.E. Isakson, B.R. Kwak, Connexins in vascular physiology and pa-
thology, Antioxid. Redox Signal. 11 (2009) 267–282.
[104] K.E.L. Scheckenbach, S. Crespin, B.R. Kwak, M. Chanson, Connexin channel-
dependent signaling pathways in inﬂammation, J. Vasc. Res. 48 (2011) 91–103.
91A. Baroja-Mazo et al. / Biochimica et Biophysica Acta 1828 (2013) 79–93[105] C.W. Wong, T. Christen, I. Roth, C.E. Chadjichristos, J.P. Derouette, B.F. Foglia, M.
Chanson, D.A. Goodenough, B.R. Kwak, Connexin37 protects against atheroscle-
rosis by regulating monocyte adhesion, Nat. Med. 12 (2006) 950–954.
[106] A. Zernecke, K. Bidzhekov, B. Ozuyaman, L. Fraemohs, E.A. Liehn, J.M. Luscher--
Firzlaff, B. Luscher, J. Schrader, C. Weber, CD73/ecto-5′-nucleotidase protects
against vascular inﬂammation and neointima formation, Circulation 113
(2006) 2120–2127.
[107] J.P. Blackburn, N.S. Peters, H.I. Yeh, S. Rothery, C.R. Green, N.J. Severs, Upregula-
tion of connexin43 gap junctions during early stages of human coronary athero-
sclerosis, Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1219–1228.
[108] C.E. Chadjichristos, K.E. Scheckenbach, T.A. van Veen, M.Z. Richani Sarieddine, C. de
Wit, Z. Yang, I. Roth, M. Bacchetta, H. Viswambharan, B. Foglia, T. Dudez, M.J. van
Kempen, F.E. Coenjaerts, L. Miquerol, U. Deutsch, H.J. Jongsma, M. Chanson, B.R.
Kwak, Endothelial-speciﬁc deletion of connexin40 promotes atherosclerosis by in-
creasing CD73-dependent leukocyte adhesion, Circulation 121 (2010) 123–131.
[109] A.H. Faraji, P. Wipf, Nanoparticles in cellular drug delivery, Bioorg. Med. Chem.
17 (2009) 2950–2962.
[110] S. Singh, H.S. Nalwa, Nanotechnology and health safety–toxicity and risk assess-
ments of nanostructured materials on human health, J. Nanosci. Nanotechnol. 7
(2007) 3048–3070.
[111] G. Bhabra, A. Sood, B. Fisher, L. Cartwright, M. Saunders, W.H. Evans, A. Surpre-
nant, G. Lopez-Castejon, S. Mann, S.A. Davis, L.A. Hails, E. Ingham, P. Verkade, J.
Lane, K. Heesom, R. Newson, C.P. Case, Nanoparticles can cause DNA damage
across a cellular barrier, Nat. Nanotechnol. 4 (2009) 876–883.
[112] F. Liu, M.J. Soares, K.L. Audus, Permeability properties of monolayers of the
human trophoblast cell line BeWo, Am. J. Physiol. 273 (1997) C1596–C1604.
[113] T. Xia, M. Kovochich, M. Liong, J.I. Zink, A.E. Nel, Cationic polystyrene nano-
sphere toxicity depends on cell-speciﬁc endocytic and mitochondrial injury
pathways, ACS Nano 2 (2008) 85–96.
[114] M.U. Baumann, S. Zamudio, N.P. Illsley, Hypoxic upregulation of glucose trans-
porters in BeWo choriocarcinoma cells is mediated by hypoxia-inducible
factor-1, Am. J. Physiol. Cell Physiol. 293 (2007) C477–C485.
[115] W.G. Junger, Immune cell regulation by autocrine purinergic signalling, Nat. Rev.
Immunol. 11 (2011) 201–212.
[116] Y. Chen, R. Corriden, Y. Inoue, L. Yip, N. Hashiguchi, A. Zinkernagel, V. Nizet, P.A.
Insel, W.G. Junger, ATP release guides neutrophil chemotaxis via P2Y2 and A3
receptors, Science 314 (2006) 1792–1795.
[117] M. Kronlage, J. Song, L. Sorokin, K. Isfort, T. Schwerdtle, J. Leipziger, B. Robaye, P.B.
Conley, H.-C. Kim, S. Sargin, P. Schön, A. Schwab, P.J. Hanley, Autocrine purinergic re-
ceptor signaling is essential for macrophage chemotaxis, Sci. Signal. 3 (2010) ra55.
[118] L. Wang, S.E. Jacobsen, A. Bengtsson, D. Erlinge, P2 receptor mRNA expression
proﬁles in human lymphocytes, monocytes and CD34+ stem and progenitor
cells, BMC Immunol. 5 (2004) 16.
[119] T. Woehrle, L. Yip, A. Elkhal, Y. Sumi, Y. Chen, Y. Yao, P.A. Insel, W.G. Junger,
Pannexin-1 hemichannel-mediated ATP release together with P2X1 and
P2X4 receptors regulate T-cell activation at the immune synapse, Blood 116
(2010) 3475–3484.
[120] U. Schenk, A.M.Westendorf, E. Radaelli, A. Casati, M. Ferro, M. Fumagalli, C. Verderio,
J. Buer, E. Scanziani, F. Grassi, Purinergic control of T cell activation by ATP released
through pannexin-1 hemichannels, Sci. Signal. 1 (2008) ra6.
[121] L. Yip, T. Woehrle, R. Corriden, M. Hirsh, Y. Chen, Y. Inoue, V. Ferrari, P.A. Insel,
W.G. Junger, Autocrine regulation of T-cell activation by ATP release and P2X7
receptors, FASEB J. 23 (2009) 1685–1693.
[122] T. Woehrle, L. Yip, M. Manohar, Y. Sumi, Y. Yao, Y. Chen, W.G. Junger, Hypertonic
stress regulates T cell function via pannexin-1 hemichannels and P2X receptors,
J. Leukoc. Biol. 88 (2010) 1181–1189.
[123] K. Atarashi, J. Nishimura, T. Shima, Y. Umesaki, M. Yamamoto, M. Onoue, H.
Yagita, N. Ishii, R. Evans, K. Honda, K. Takeda, ATP drives lamina propria T(H)
17 cell differentiation, Nature 455 (2008) 808–812.
[124] S. Padeh, A. Cohen, C.M. Roifman, ATP-induced activation of human B lympho-
cytes via P2-purinoceptors, J. Immunol. 146 (1991) 1626–1632.
[125] S. Deaglio, K.M. Dwyer,W. Gao, D. Friedman, A. Usheva, A. Erat, J.F. Chen, K. Enjyoji,
J. Linden, M. Oukka, V.K. Kuchroo, T.B. Strom, S.C. Robson, Adenosine generation
catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune
suppression, J. Exp. Med. 204 (2007) 1257–1265.
[126] F.B. Chekeni, M.R. Elliott, J.K. Sandilos, S.F. Walk, J.M. Kinchen, E.R. Lazarowski,
A.J. Armstrong, S. Penuela, D.W. Laird, G.S. Salvesen, B.E. Isakson, D.A. Bayliss,
K.S. Ravichandran, Pannexin 1 channels mediate ‘ﬁnd-me’ signal release and
membrane permeability during apoptosis, Nature 467 (2010) 863–867.
[127] Y. Qu, S. Misaghi, K. Newton, L.L. Gilmour, S. Louie, J.E. Cupp, G.R. Dubyak, D.
Hackos, V.M. Dixit, Pannexin-1 is required for ATP release during apoptosis
but not for inﬂammasome activation, J. Immunol. 186 (2011) 6553–6561.
[128] S. Honda, Y. Sasaki, K. Ohsawa, Y. Imai, Y. Nakamura, K. Inoue, S. Kohsaka, Extra-
cellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o--
coupled P2Y receptors, J. Neurosci. 21 (2001) 1975–1982.
[129] M. Schnurr, T. Toy, P. Stoitzner, P. Cameron, A. Shin, T. Beecroft, I.D. Davis, J.
Cebon, E. Maraskovsky, ATP gradients inhibit the migratory capacity of speciﬁc
human dendritic cell types: implications for P2Y11 receptor signaling, Blood
102 (2003) 613–620.
[130] A. Piccini, S. Carta, S. Tassi, D. Lasiglie, G. Fossati, A. Rubartelli, ATP is released by
monocytes stimulated with pathogen-sensing receptor ligands and induces
IL-1beta and IL-18 secretion in an autocrine way, Proc. Natl. Acad. Sci. U. S. A.
105 (2008) 8067–8072.
[131] F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T.
Panaretakis, G. Mignot, E. Ullrich, J.L. Perfettini, F. Schlemmer, E. Tasdemir, M.
Uhl, P. Genin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. Andre, R. Lidereau,N.M. McLaughlin, N.M. Haynes, M.J. Smyth, G. Kroemer, L. Zitvogel, Activation of
the NLRP3 inﬂammasome in dendritic cells induces IL-1beta-dependent adaptive
immunity against tumors, Nat. Med. 15 (2009) 1170–1178.
[132] R.C. Boucher, Regulation of airway surface liquid volume by human airway epi-
thelia, Pﬂugers Arch. 445 (2003) 495–498.
[133] E.R. Lazarowski, R.C. Boucher, Purinergic receptors in airway epithelia, Curr.
Opin. Pharmacol. 9 (2009) 262–267.
[134] L. Seminario-Vidal, S.F. Okada, J.I. Sesma, S.M. Kreda, C.A. van Heusden, Y. Zhu,
L.C. Jones, W.K. O'Neal, S. Penuela, D.W. Laird, R.C. Boucher, E.R. Lazarowski,
Rho signaling regulates pannexin 1-mediated ATP release from airway epithelia,
J. Biol. Chem. 286 (2011) 26277–26286.
[135] G.A. Ransford, N. Fregien, F. Qiu, G. Dahl, G.E. Conner, M. Salathe, Pannexin 1
contributes to atp release in airway epithelia, Am. J. Respir. Cell Mol. Biol. 41
(2009) 525–534.
[136] C.W. Davis, B.F. Dickey, Regulated airway goblet cell mucin secretion, Annu. Rev.
Physiol. 70 (2008) 487–512.
[137] A. Caputo, E. Caci, L. Ferrera, N. Pedemonte, C. Barsanti, E. Sondo, U. Pfeffer, R.
Ravazzolo, O. Zegarra-Moran, L.J. Galietta, TMEM16A, a membrane protein asso-
ciated with calcium-dependent chloride channel activity, Science 322 (2008)
590–594.
[138] C. Seror, M.T. Melki, F. Subra, S.Q. Raza, M. Bras, H. Saidi, R. Nardacci, L. Voisin, A.
Paoletti, F. Law, I. Martins, A. Amendola, A.A. Abdul-Sater, F. Ciccosanti, O. Delelis,
F. Niedergang, S. Thierry, N. Said-Sadier, C. Lamaze, D. Metivier, J. Estaquier, G.M.
Fimia, L. Falasca, R. Casetti, N. Modjtahedi, J. Kanellopoulos, J.F. Mouscadet, D.M.
Ojcius, M. Piacentini, M.L. Gougeon, G. Kroemer, J.L. Perfettini, Extracellular ATP
acts on P2Y2 purinergic receptors to facilitate HIV-1 infection, J. Exp. Med. 208
(2011) 1823–1834.
[139] W. Hubner, G.P. McNerney, P. Chen, B.M. Dale, R.E. Gordon, F.Y. Chuang, X.D. Li,
D.M. Asmuth, T. Huser, B.K. Chen, Quantitative 3D video microscopy of HIV
transfer across T cell virological synapses, Science 323 (2009) 1743–1747.
[140] S. Lev, H. Moreno, R. Martinez, P. Canoll, E. Peles, J.M. Musacchio, G.D. Plowman,
B. Rudy, J. Schlessinger, Protein tyrosine kinase PYK2 involved in Ca(2+)-in-
duced regulation of ion channel and MAP kinase functions, Nature 376 (1995)
737–745.
[141] R.A. Romanov, O.A. Rogachevskaja, M.F. Bystrova, P. Jiang, R.F. Margolskee, S.S.
Kolesnikov, Afferent neurotransmission mediated by hemichannels in mamma-
lian taste cells, EMBO J. 26 (2007) 657–667.
[142] R. Dando, S.D. Roper, Cell-to-cell communication in intact taste buds through
ATP signalling from pannexin 1 gap junction hemichannels, J. Physiol. 587
(2009) 5899–5906.
[143] Y.A. Huang, S.D. Roper, Intracellular Ca2+ and TRPM5-mediated membrane de-
polarization produce ATP secretion from taste receptor cells, J. Physiol. 588
(2010) 2343–2350.
[144] Y.J. Huang, Y. Maruyama, K.S. Lu, E. Pereira, I. Plonsky, J.E. Baur, D. Wu, S.D.
Roper, Mouse taste buds use serotonin as a neurotransmitter, J. Neurosci. 25
(2005) 843–847.
[145] T.E. Finger, V. Danilova, J. Barrows, D.L. Bartel, A.J. Vigers, L. Stone, G. Hellekant,
S.C. Kinnamon, ATP signaling is crucial for communication from taste buds to
gustatory nerves, Science 310 (2005) 1495–1499.
[146] Y.A. Huang, R. Dando, S.D. Roper, Autocrine and paracrine roles for ATP and se-
rotonin in mouse taste buds, J. Neurosci. 29 (2009) 13909–13918.
[147] S. Locovei, L. Bao, G. Dahl, Pannexin 1 in erythrocytes: function without a gap,
Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 7655–7659.
[148] H. Jiang, A.G. Zhu, M. Mamczur, J.R. Falck, K.M. Lerea, J.C. McGiff, Stimulation of
rat erythrocyte P2X7 receptor induces the release of epoxyeicosatrienoic acids,
Br. J. Pharmacol. 151 (2007) 1033–1040.
[149] V. Resta, E. Novelli, G. Vozzi, C. Scarpa, M. Caleo, A. Ahluwalia, A. Solini, E. Santini,
V. Parisi, F. Di Virgilio, L. Galli-Resta, Acute retinal ganglion cell injury caused by
intraocular pressure spikes is mediated by endogenous extracellular ATP, Eur. J.
Neurosci. 25 (2007) 2741–2754.
[150] X. Zhang, M. Zhang, A.M. Laties, C.H. Mitchell, Stimulation of P2X7 receptors el-
evates Ca2+ and kills retinal ganglion cells, Invest. Ophthalmol. Vis. Sci. 46
(2005) 2183–2191.
[151] D. Reigada, W. Lu, M. Zhang, C.H. Mitchell, Elevated pressure triggers a physio-
logical release of ATP from the retina: possible role for pannexin hemichannels,
Neuroscience 157 (2008) 396–404.
[152] A. Li, C.T. Leung, K. Peterson-Yantorno, C.H. Mitchell, M.M. Civan, Pathways for ATP
release by bovine ciliary epithelial cells, the initial step in purinergic regulation of
aqueous humor inﬂow, Am. J. Physiol. Cell Physiol. 299 (2010) C1308–C1317.
[153] C.W. Do, M.M. Civan, Basis of chloride transport in ciliary epithelium, J. Membr.
Biol. 200 (2004) 1–13.
[154] M. Shahidullah, W.S. Wilson, Mobilisation of intracellular calcium by P2Y2 re-
ceptors in cultured, non-transformed bovine ciliary epithelial cells, Curr. Eye
Res. 16 (1997) 1006–1016.
[155] C.W. Do, K. Peterson-Yantorno, C.H. Mitchell, M.M. Civan, cAMP-activated
maxi-Cl(−) channels in native bovine pigmented ciliary epithelial cells, Am. J.
Physiol. Cell Physiol. 287 (2004) C1003–C1011.
[156] D.A. Carre, C.H. Mitchell, K. Peterson-Yantorno, M. Coca-Prados, M.M. Civan, Sim-
ilarity of A(3)-adenosine and swelling-activated Cl(−) channels in nonpigmen-
ted ciliary epithelial cells, Am. J. Physiol. Cell Physiol. 279 (2000) C440–C451.
[157] M.L. He, A.E. Gonzalez-Iglesias, M. Tomic, S.S. Stojilkovic, Release and extracellu-
lar metabolism of ATP by ecto-nucleotidase eNTPDase 1–3 in hypothalamic and
pituitary cells, Purinergic Signal. 1 (2005) 135–144.
[158] T.A. Koshimizu, M. Tomic, A.O. Wong, D. Zivadinovic, S.S. Stojilkovic, Character-
ization of purinergic receptors and receptor-channels expressed in anterior pi-
tuitary cells, Endocrinology 141 (2000) 4091–4099.
92 A. Baroja-Mazo et al. / Biochimica et Biophysica Acta 1828 (2013) 79–93[159] S. Li, I. Bjelobaba, Z. Yan, M. Kucka, M. Tomic, S.S. Stojilkovic, Expression and
roles of pannexins in ATP release in the pituitary gland, Endocrinology 152
(2011) 2342–2352.
[160] S. Li, M. Tomić, S.S. Stojilkovic, Characterization of novel Pannexin 1 isoforms
from rat pituitary cells and their association with ATP-gated P2X channels,
Gen. Comp. Endocrinol. 174 (2011) 202–210.
[161] J.D. Troadec, S. Thirion, Multifaceted purinergic regulation of
stimulus-secretion coupling in the neurohypophysis, Neuro Endocrinol. Lett.
23 (2002) 273–280.
[162] S.S. Stojilkovic, M.L. He, T.A. Koshimizu, A. Balik, H. Zemkova, Signaling by puri-
nergic receptors and channels in the pituitary gland, Mol. Cell. Endocrinol. 314
(2010) 184–191.
[163] J.R. Kapoor, C.D. Sladek, Purinergic and adrenergic agonists synergize in stimu-
lating vasopressin and oxytocin release, J. Neurosci. 20 (2000) 8868–8875.
[164] H. Zemkova, A. Balik, Y. Jiang, K. Kretschmannova, S.S. Stojilkovic, Roles of puriner-
gic P2X receptors as pacemaking channels and modulators of calcium-mobilizing
pathway in pituitary gonadotrophs, Mol. Endocrinol. 20 (2006) 1423–1436.
[165] J.D. Troadec, S. Thirion, D. Petturiti, M.T. Bohn, P. Poujeol, ATP acting on P2Y re-
ceptors triggers calcium mobilization in primary cultures of rat neurohypophy-
sial astrocytes (pituicytes), Pﬂugers Arch. 437 (1999) 745–753.
[166] S. Buvinic, G. Almarza, M. Bustamante, M. Casas, J. Lopez, M. Riquelme, J.C. Saez,
J.P. Huidobro-Toro, E. Jaimovich, ATP released by electrical stimuli elicits calcium
transients and gene expression in skeletal muscle, J. Biol. Chem. 284 (2009)
34490–34505.
[167] N. Juretic, U. Urzua, D.J. Munroe, E. Jaimovich, N. Riveros, Differential gene ex-
pression in skeletal muscle cells after membrane depolarization, J. Cell. Physiol.
210 (2007) 819–830.
[168] S. Cockcroft, B.D. Gomperts, ATP induces nucleotide permeability in rat mast
cells, Nature 279 (1979) 541–542.
[169] E. Rozengurt, L.A. Heppel, A Speciﬁc effect of external ATP on the permeability of
transformed 3 T3 cells, Biochem. Biophys. Res. Commun. 67 (1975) 1581–1588.
[170] P. Pelegrín, Many ways to dilate the P2X7 receptor pore, Br. J. Pharmacol. 163
(2011) 908–911.
[171] D.A. Iacobas, S.O. Suadicani, S. Iacobas, C. Chrisman, M.A. Cohen, D.C. Spray, E.
Scemes, Gap junction and purinergic P2 receptor proteins as a functional unit:
insights from transcriptomics, J. Membr. Biol. 217 (2007) 83–91.
[172] E. Scemes, D.C. Spray, P. Meda, Connexins, pannexins, innexins: novel roles of
“hemi-channels”, Pﬂugers Arch. 457 (2009) 1207–1226.
[173] S. Locovei, J. Wang, G. Dahl, Activation of pannexin 1 channels by ATP through
P2Y receptors and by cytoplasmic calcium, FEBS Lett. 580 (2006) 239–244.
[174] A. Surprenant, F.-A. Rassendren, E. Kawashima, R.A. North, G. Buell, The cytolytic
P2Z receptor for extracellular ATP identiﬁed as a P2X receptor (P2X7), Science
272 (1996) 735–738.
[175] E.C. Beyer, T.H. Steinberg, Evidence that the gap junction protein connexin-43 is
the ATP-induced pore of mouse macrophages, J. Biol. Chem. 266 (1991)
7971–7974.
[176] L.A. Alves, R. Coutinho-Silva, P.M. Persechini, D.C. Spray, W. Savino, A.C. Campos
de Carvalho, Are there functional gap junctions or junctional hemichannels in
macrophages? Blood 88 (1996) 328–334.
[177] P. Pelegrin, A. Surprenant, Pannexin-1 mediates large pore formation and
interleukin-1beta release by the ATP-gated P2X7 receptor, EMBO J. 25 (2006)
5071–5082.
[178] S. Locovei, E. Scemes, F. Qiu, D.C. Spray, G. Dahl, Pannexin1 is part of the pore
forming unit of the P2X(7) receptor death complex, FEBS Lett. 581 (2007)
483–488.
[179] R. Iglesias, S. Locovei, A. Roque, A.P. Alberto, G. Dahl, D.C. Spray, E. Scemes, P2X7
receptor–Pannexin1 complex: pharmacology and signaling, Am. J. Physiol. Cell
Physiol. 295 (2008) C752–C760.
[180] W. Ma, H. Hui, P. Pelegrin, A. Surprenant, Pharmacological characterization of
pannexin-1 currents expressed in mammalian cells, J. Pharmacol. Exp. Ther.
328 (2009) 409–418.
[181] W. Silverman, S. Locovei, G. Dahl, Probenecid, a gout remedy, inhibits pannexin
1 channels, Am. J. Physiol. Cell Physiol. 295 (2008) C761–C767.
[182] J. Schachter, A.P.Motta, A. de Souza Zamorano, H.A. da Silva-Souza,M.Z.P. Guimarães,
P.M. Persechini, ATP-induced P2X7-associated uptake of large molecules involves
distinct mechanisms for cations and anions in macrophages, J. Cell Sci. 121 (2008)
3261–3270.
[183] S. Bunse, S. Locovei, M. Schmidt, F. Qiu, G. Zoidl, G. Dahl, R. Dermietzel, The po-
tassium channel subunit Kvbeta3 interacts with pannexin 1 and attenuates its
sensitivity to changes in redox potentials, FEBS J. 276 (2009) 6258–6270.
[184] W.H. Evans, E. De Vuyst, L. Leybaert, The gap junction cellular internet: connexin
hemichannels enter the signalling limelight, Biochem. J. 397 (2006) 1–14.
[185] G. Dahl, Gap junction-mimetic peptides do work, but in unexpected ways, Cell
Commun. Adhes. 14 (2007) 259–264.
[186] V. Poornima, M. Madhupriya, S. Kootar, G. Sujatha, A. Kumar, A.K. Bera, P2X(7)
receptor-pannexin 1 hemichannel association: effect of extracellular calcium
on membrane permeabilization, J. Mol. Neurosci. (2011), doi:10.1007/s12031-
12011-19646-12038.
[187] S. Cankurtaran-Sayar, K. Sayar, M. Ugur, P2X7 receptor activates multiple selec-
tive dye-permeation pathways in RAW 264.7 and human embryonic kidney 293
cells, Mol. Pharmacol. 76 (2009) 1323–1332.
[188] I. Lemaire, S. Falzoni, B. Zhang, P. Pellegatti, F. Di Virgilio, The P2X7 receptor and
pannexin-1 are both required for the promotion of multinucleated macrophages
by the inﬂammatory cytokine GM-CSF, J. Immunol. 187 (2011) 3878–3887.
[189] A. Baranova, D. Ivanov, N. Petrash, A. Pestova, M. Skoblov, I. Kelmanson, D.
Shagin, S. Nazarenko, E. Geraymovych, O. Litvin, A. Tiunova, T.L. Born, N. Usman,D. Staroverov, S. Lukyanov, Y. Panchin, The mammalian pannexin family is homol-
ogous to the invertebrate innexin gap junction proteins, Genomics 83 (2004)
706–716.
[190] S. Chaumont, B.S. Khakh, Patch-clamp coordinated spectroscopy shows P2X2
receptor permeability dynamics require cytosolic domain rearrangements
but not Panx-1 channels, Proc. Natl. Acad. Sci. U. S. A. 105 (2008)
12063–12068.
[191] C. Virginio, A. MacKenzie, F.A. Rassendren, R.A. North, A. Surprenant, Pore dila-
tion of neuronal P2X receptor channels, Nat. Neurosci. 2 (1999) 315–321.
[192] C.Marques-Da-Silva,M.M. Chaves, N.G. Castro, R. Coutinho-Silva,M.Z.P. Guimaraes,
Colchicine inhibits cationic dye uptake induced by ATP in P2X2 and P2X7
receptor-expressing cells: implications for its therapeutic action, Br. J. Pharmacol.
163 (2011) 912–926.
[193] J.A. Fisher, G. Girdler, B.S. Khakh, Time-resolved measurement of state-speciﬁc
P2X2 ion channel cytosolic gating motions, J. Neurosci. 24 (2004)
10475–10487.
[194] Y. Shinozaki, K. Sumitomo, M. Tsuda, S. Koizumi, K. Inoue, K. Torimitsu, Direct
observation of ATP-induced conformational changes in single P2X4 receptors,
PLoS Biol. 7 (2009) e103.
[195] Z. Yan, A. Khadra, S. Li,M. Tomic, A. Sherman, S.S. Stojilkovic, Experimental character-
ization and mathematical modeling of P2X7 receptor channel gating, J. Neurosci. 30
(2010) 14213–14224.
[196] B.S. Khakh, X.R. Bao, C. Labarca, H.A. Lester, Neuronal P2X transmitter-gated cat-
ion channels change their ion selectivity in seconds, Nat. Neurosci. 2 (1999)
322–330.
[197] C. Guo, M. Masin, O.S. Qureshi, R.D. Murrell-Lagnado, Evidence for functional
P2X4/P2X7 heteromeric receptors, Mol. Pharmacol. 72 (2007) 1447–1456.
[198] K. Braet, W. Vandamme, P.E. Martin, W.H. Evans, L. Leybaert, Photoliberating
inositol-1,4,5-trisphosphate triggers ATP release that is blocked by the connexin
mimetic peptide gap 26, Cell Calcium 33 (2003) 37–48.
[199] R.A. Pearson, N. Dale, E. Llaudet, P. Mobbs, ATP released via gap junction hemi-
channels from the pigment epithelium regulates neural retinal progenitor pro-
liferation, Neuron 46 (2005) 731–744.
[200] E.C.Y. Wang, J.-M. Lee, W.G. Ruiz, E.M. Balestreire, M. von Bodungen, S. Barrick,
D.A. Cockayne, L.A. Birder, G. Apodaca, ATP and purinergic receptor-dependent
membrane trafﬁc in bladder umbrella cells, J. Clin. Invest. 115 (2005)
2412–2422.
[201] S.O. Suadicani, C.E. Flores, M. Urban-Maldonado, M. Beelitz, E. Scemes, Gap junc-
tion channels coordinate the propagation of intercellular Ca2+ signals generated
by P2Y receptor activation, Glia 48 (2004) 217–229.
[202] E. Scemes, C. Giaume, Astrocyte calcium waves: what they are and what they do,
Glia 54 (2006) 716–725.
[203] S.J. Smith, Neural signalling. Neuromodulatory astrocytes, Curr. Biol. 4 (1994)
807–810.
[204] Y. Osipchuk, M. Cahalan, Cell-to-cell spread of calcium signals mediated by ATP
receptors in mast cells, Nature 359 (1992) 241–244.
[205] E. Scemes, S.O. Suadicani, D.C. Spray, Intercellular communication in spinal cord
astrocytes: ﬁne tuning between gap junctions and P2 nucleotide receptors in
calcium wave propagation, J. Neurosci. 20 (2000) 1435–1445.
[206] J.X. Jiang, P.P. Cherian, Hemichannels formed by connexin 43 play an important
role in the release of prostaglandin E(2) by osteocytes in response to mechanical
strain, Cell Commun. Adhes. 10 (2003) 259–264.
[207] P.P. Cherian, A.J. Siller-Jackson, S. Gu, X. Wang, L.F. Bonewald, E. Sprague, J.X.
Jiang, Mechanical strain opens connexin 43 hemichannels in osteocytes: a
novel mechanism for the release of prostaglandin, Mol. Biol. Cell 16 (2005)
3100–3106.
[208] L. Ulmann, H. Hirbec, F.-A. Rassendren, P2X4 receptors mediate PGE2 release by
tissue-resident macrophages and initiate inﬂammatory pain, EMBO J. 29 (2010)
2290–2300.
[209] C.M. Blatteis, The onset of fever: new insights into its mechanism, Prog. Brain
Res. 162 (2007) 3–14.
[210] P. Pelegrin, C. Barroso-Gutierrez, A. Surprenant, P2X7 receptor differentially
couples to distinct release pathways for IL-1beta in mouse macrophage, J.
Immunol. 180 (2008) 7147–7157.
[211] T.-D. Kanneganti, M. Lamkanﬁ, Y.-G. Kim, G. Chen, J.-H. Park, L. Franchi, P.
Vandenabeele, G. Nunez, Pannexin-1-mediated recognition of bacterial mole-
cules activates the cryopyrin inﬂammasome independent of Toll-like receptor sig-
naling, Immunity 26 (2007) 433–443.
[212] K. Schroder, J. Tschopp, The inﬂammasomes, Cell 140 (2010) 821–832.
[213] W. Silverman, J. De Rivero Vaccari, S. Locovei, F. Qiu, S. Carlsson, E. Scemes, R.
Keane, G. Dahl, The pannexin 1 channel activates the inﬂammasome in neurons
and astrocytes, J. Biol. Chem. 284 (2009) 18143–18151.
[214] P. Pelegrin, Inﬂammasome activation by danger signals, in: I. Couillin, V. Petrilli,
F. Martinon (Eds.), The Inﬂammasomes, Srpinger Basel, 2011, pp. 101–121.
[215] J.A. Orellana, P.J. Sáez, K.F. Shoji, K.A. Schalper, N. Palacios-Prado, V. Velarde, C.
Giaume, M.V.L. Bennett, J.C. Sáez, Modulation of brain hemichannels and gap
junction channels by pro-inﬂammatory agents and their possible role in neuro-
degeneration, Antioxid. Redox Signal. 11 (2009) 369–399.
[216] J.A. Orellana, N. Froger, P. Ezan, J.X. Jiang, M.V.L. Bennett, C.C. Naus, C. Giaume,
J.C. Sáez, ATP and glutamate released via astroglial connexin 43 hemichannels
mediate neuronal death through activation of pannexin 1 hemichannels, J. Neu-
rochem. 118 (2011) 826–840.
[217] N. Marina-García, L. Franchi, Y.-G. Kim, D. Miller, C. McDonald, G.-J. Boons, G.
Nunez, Pannexin-1-mediated intracellular delivery of muramyl dipeptide in-
duces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2, J.
Immunol. 180 (2008) 4050–4057.
93A. Baroja-Mazo et al. / Biochimica et Biophysica Acta 1828 (2013) 79–93[218] Z.C. Ye, M.S. Wyeth, S. Baltan-Tekkok, B.R. Ransom, Functional hemichannels in
astrocytes: a novel mechanism of glutamate release, J. Neurosci. 23 (2003)
3588–3596.
[219] H. Takeuchi, S. Jin, J. Wang, G. Zhang, J. Kawanokuchi, R. Kuno, Y. Sonobe, T.
Mizuno, A. Suzumura, Tumor necrosis factor-alpha induces neurotoxicity via
glutamate release from hemichannels of activated microglia in an autocrine
manner, J. Biol. Chem. 281 (2006) 21362–21368.
[220] G.S. Goldberg, A.P. Moreno, P.D. Lampe, Gap junctions between cells expressing
connexin 43 or 32 show inverse permselectivity to adenosine and ATP, J. Biol.
Chem. 277 (2002) 36725–36730.[221] V. Valiunas, Y.Y. Polosina, H. Miller, I.A. Potapova, L. Valiuniene, S. Doronin, R.T.
Mathias, R.B. Robinson, M.R. Rosen, I.S. Cohen, P.R. Brink, Connexin-speciﬁc
cell-to-cell transfer of short interfering RNA by gap junctions, J. Physiol. 568
(2005) 459–468.
[222] J. Neijssen, C. Herberts, J.W. Drijfhout, E. Reits, L. Janssen, J. Neefjes, Cross--
presentation by intercellular peptide transfer through gap junctions, Nature
434 (2005) 83–88.
[223] D.A. Vessey, L. Li, M. Kelley, Pannexin-I/P2X 7 purinergic receptor channels me-
diate the release of cardioprotectants induced by ischemic pre- and postcondi-
tioning, J. Cardiovasc. Pharmacol. Ther. 15 (2010) 190–195.
